<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.1 20151215//EN" "https://jats.nlm.nih.gov/publishing/1.1/JATS-journalpublishing1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" specific-use="sps-1.9" dtd-version="1.1" xml:lang="pt" article-type="research-article">
  <front>
    <journal-meta>
      <journal-id journal-id-type="publisher-id">abc</journal-id>
      <journal-title-group>
        <journal-title>Arquivos Brasileiros de Cardiologia</journal-title>
        <abbrev-journal-title abbrev-type="publisher">Arq. Bras. Cardiol.</abbrev-journal-title>
      </journal-title-group>
      <issn pub-type="ppub">0066-782X</issn>
      <issn pub-type="epub">1678-4170</issn>
      <publisher>
        <publisher-name>Sociedade Brasileira de Cardiologia - SBC</publisher-name>
        <publisher-loc>S&#227;o Paulo, SP, Brazil</publisher-loc>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="publisher-id" specific-use="scielo-v3">fsmMtnXtvMN79YqvbgyTnct</article-id>
      <article-id pub-id-type="other">00020</article-id>
      <article-id pub-id-type="publisher-id" specific-use="scielo-v2">S0066-782X2011000300020</article-id>
      <article-id pub-id-type="publisher-id" specific-use="scielo-v1">S0066-782X(11)09600320</article-id>
      <article-id pub-id-type="doi">10.1590/S0066-782X2011005000018</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Artigos Originais</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>T-wave alternans: desempenho cl&#237;nico, limita&#231;&#245;es, metodologias de an&#225;lise</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Garcia</surname>
            <given-names>Euler V.</given-names>
          </name>
          <xref ref-type="aff" rid="aff01"/>
          <xref ref-type="aff" rid="aff02"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Pastore</surname>
            <given-names>Carlos Alberto</given-names>
          </name>
          <xref ref-type="aff" rid="aff01"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Samesima</surname>
            <given-names>Nelson</given-names>
          </name>
          <xref ref-type="aff" rid="aff01"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Pereira Filho</surname>
            <given-names>Hor&#225;cio G.</given-names>
          </name>
          <xref ref-type="aff" rid="aff01"/>
        </contrib>
      </contrib-group>
      <aff id="aff01">
        <addr-line>
          <named-content content-type="state">S&#227;o Paulo</named-content>
        </addr-line>
        <institution content-type="orgname">Universidade de S&#227;o Paulo</institution>
        <institution content-type="orgdiv1">Faculdade de Medicina </institution>
        <institution content-type="orgdiv2">Hospital das Cl&#237;nicas</institution>
        <country country="BR">Brazil</country>
      </aff>
      <aff id="aff02">
        <addr-line>
          <named-content content-type="city">Bras&#237;lia</named-content>
          <named-content content-type="state">Distrito Federal</named-content>
        </addr-line>
        <institution content-type="orgname">Universidade de Bras&#237;lia</institution>
        <country country="BR">Brazil</country>
      </aff>
      <pub-date date-type="collection" publication-format="electronic">
        <month>03</month>
        <year>2011</year>
      </pub-date>
      <volume>96</volume>
      <issue>3</issue>
      <fpage>e53</fpage>
      <lpage>e61</lpage>
      <history>
        <date date-type="accepted">
          <day>18</day>
          <month>03</month>
          <year>2010</year>
        </date>
        <date date-type="rev-recd">
          <day>29</day>
          <month>05</month>
          <year>2009</year>
        </date>
        <date date-type="received">
          <day>19</day>
          <month>03</month>
          <year>2009</year>
        </date>
      </history>
      <permissions>
        <license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc/4.0/" xml:lang="en">
          <license-p>This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.</license-p>
        </license>
      </permissions>
      <abstract>
        <p>Reconhecer com precis&#227;o indiv&#237;duos com maior risco imediato de morte s&#250;bita card&#237;aca (MSC) ainda &#233; uma quest&#227;o em aberto. A natureza fortuita dos eventos cardiovasculares agudos n&#227;o parece se adequar ao conhecido modelo de indu&#231;&#227;o de taquicardia/fibrila&#231;&#227;o ventricular por um gatilho em sincronia a um substrato arritmog&#234;nico est&#225;tico. Quanto ao mecanismo da MSC, uma instabilidade el&#233;trica din&#226;mica explicaria melhor a raridade da associa&#231;&#227;o simult&#226;nea de um gatilho certo a um substrato card&#237;aco apropriado. Diversos estudos tentaram medir essa instabilidade el&#233;trica card&#237;aca (ou um equivalente v&#225;lido) em uma sequ&#234;ncia de batimentos card&#237;acos no ECG. Dentre os mecanismos poss&#237;veis podemos citar o prolongamento do QT, dispers&#227;o do QT, potenciais tardios, altern&#226;ncia de onda T ou T-wave alternans (TWA), e turbul&#234;ncia da frequ&#234;ncia card&#237;aca. Este artigo se at&#233;m em particular ao papel da TWA no panorama atual da estratifica&#231;&#227;o de risco card&#237;aco. Os achados sobre TWA ainda s&#227;o heterog&#234;neos, variando de um desempenho progn&#243;stico muito bom at&#233; um quase nulo, dependendo da popula&#231;&#227;o cl&#237;nica observada e protocolo cl&#237;nico usado. Para preencher as atuais lacunas no conhecimento sobre TWA, profissionais m&#233;dicos e pesquisadores devem explorar melhor as caracter&#237;sticas t&#233;cnicas das diversas tecnologias dispon&#237;veis para a avalia&#231;&#227;o de TWA e atentar ao fato de que os valores de TWA respondem a diversos outros fatores, al&#233;m de medicamentos. Informa&#231;&#245;es sobre mecanismos celulares e subcelulares da TWA est&#227;o fora do escopo deste artigo, mas s&#227;o referenciados alguns dos principais trabalhos sobre este t&#243;pico, com o intuito de auxiliar no entendimento dos conceitos e fatos cobertos neste artigo.</p>
      </abstract>
      <kwd-group xml:lang="pt" kwd-group-type="author-generated">
        <kwd>Arritmias card&#237;acas</kwd>
        <kwd>morte s&#250;bita</kwd>
        <kwd>desfibriladores implant&#225;veis</kwd>
        <kwd>Estados Unidos</kwd>
      </kwd-group>
      <pub-date publication-format="electronic" date-type="pub">
        <day>25</day>
        <month>02</month>
        <year>2011</year>
      </pub-date>
    </article-meta>
  </front>
  <body>
    <p>
      <bold>T-wave alternans: desempenho cl&#237;nico, limita&#231;&#245;es, metodologias de an&#225;lise</bold>
    </p>
    <p>
      <bold>Euler V. Garcia<sup>I, II</sup>; Carlos Alberto Pastore<sup>I</sup>; Nelson Samesima<sup>I</sup>; Hor&#225;cio G. Pereira Filho<sup>I</sup></bold>
    </p>
    <p><sup>I</sup>Servi&#231;o de Eletrocardiologia - Instituto do Cora&#231;&#227;o (InCor) do Hospital das Cl&#237;nicas - Faculdade de Medicina da Universidade de S&#227;o Paulo, S&#227;o Paulo, SP </p>
    <p><sup>II</sup>Universidade de Bras&#237;lia - Campus Gama, Bras&#237;lia, DF - Brasil</p>
    <p>
      <xref ref-type="corresp" rid="back">Correspond&#234;ncia</xref>
    </p>
    <p>
      <bold>RESUMO</bold>
    </p>
    <p>Reconhecer com precis&#227;o indiv&#237;duos com maior risco imediato de morte s&#250;bita card&#237;aca (MSC) ainda &#233; uma quest&#227;o em aberto. A natureza fortuita dos eventos cardiovasculares agudos n&#227;o parece se adequar ao conhecido modelo de indu&#231;&#227;o de taquicardia/fibrila&#231;&#227;o ventricular por um gatilho em sincronia a um substrato arritmog&#234;nico est&#225;tico. Quanto ao mecanismo da MSC, uma instabilidade el&#233;trica din&#226;mica explicaria melhor a raridade da associa&#231;&#227;o simult&#226;nea de um gatilho certo a um substrato card&#237;aco apropriado. Diversos estudos tentaram medir essa instabilidade el&#233;trica card&#237;aca (ou um equivalente v&#225;lido) em uma sequ&#234;ncia de batimentos card&#237;acos no ECG. Dentre os mecanismos poss&#237;veis podemos citar o prolongamento do QT, dispers&#227;o do QT, potenciais tardios, altern&#226;ncia de onda T ou T-wave alternans (TWA), e turbul&#234;ncia da frequ&#234;ncia card&#237;aca. Este artigo se at&#233;m em particular ao papel da TWA no panorama atual da estratifica&#231;&#227;o de risco card&#237;aco. Os achados sobre TWA ainda s&#227;o heterog&#234;neos, variando de um desempenho progn&#243;stico muito bom at&#233; um quase nulo, dependendo da popula&#231;&#227;o cl&#237;nica observada e protocolo cl&#237;nico usado. Para preencher as atuais lacunas no conhecimento sobre TWA, profissionais m&#233;dicos e pesquisadores devem explorar melhor as caracter&#237;sticas t&#233;cnicas das diversas tecnologias dispon&#237;veis para a avalia&#231;&#227;o de TWA e atentar ao fato de que os valores de TWA respondem a diversos outros fatores, al&#233;m de medicamentos. Informa&#231;&#245;es sobre mecanismos celulares e subcelulares da TWA est&#227;o fora do escopo deste artigo, mas s&#227;o referenciados alguns dos principais trabalhos sobre este t&#243;pico, com o intuito de auxiliar no entendimento dos conceitos e fatos cobertos neste artigo.</p>
    <p><bold>Palavras-chave:</bold> Arritmias card&#237;acas/preven&#231;&#227;o e controle, morte s&#250;bita/preven&#231;&#227;o e controle, desfibriladores implant&#225;veis, Estados Unidos/epidemiologia.</p>
    <p>Em geral, a maioria dos casos de morte s&#250;bita card&#237;aca (MSC) est&#225; relacionada a doen&#231;a arterial coron&#225;ria e cardiomiopatia n&#227;o isqu&#234;mica dilatada e hipertr&#243;fica<sup>1</sup>. Igualmente importantes s&#227;o os casos de MSC registrados em sujeitos aparentemente saud&#225;veis. Entre 1994 a 2003, no Reino Unido, foram realizadas aut&#243;psias de 453 indiv&#237;duos que sofreram MSC, todos entre 15 e 81 anos de idade. Nesse conjunto, foram encontrados 269 (59,3%) cora&#231;&#245;es macrosc&#243;pica e microscopicamente normais<sup>2</sup>.</p>
    <p>O reconhecimento preciso de indiv&#237;duos com maior risco imediato de MSC ainda &#233; uma quest&#227;o em aberto. Muitos fatores (adquiridos ou cong&#234;nitos; estruturais, funcionais ou gen&#233;ticos) est&#227;o relacionados a um aumento no risco de MSC, por&#233;m isoladamente eles n&#227;o conseguem apontar quando uma pessoa estar&#225; no n&#237;vel m&#225;ximo desse tipo de risco. A atividade f&#237;sica vigorosa (6 METS ou mais) pode aumentar potencialmente o risco de eventos cardiovasculares agudos, por&#233;m a raridade dos eventos relacionados ao exerc&#237;cio d&#225; uma indica&#231;&#227;o clara de que &#233; necess&#225;rio um substrato card&#237;aco espec&#237;fico adicional, segundo a declara&#231;&#227;o conjunta da <italic>American Heart Association</italic> e <italic>American College of Sports Medicine</italic><sup>3</sup>.</p>
    <p>Em outras palavras, a natureza aparentemente aleat&#243;ria de um evento cardiovascular agudo exemplifica bem que o mecanismo patofisiol&#243;gico t&#237;pico da MSC n&#227;o parece ser um gatilho em sincronismo com um substrato arritmog&#234;nico est&#225;tico, para que tenha in&#237;cio uma taquicardia ventricular (TV) ou fibrila&#231;&#227;o. Pelo contr&#225;rio, a instabilidade el&#233;trica seria din&#226;mica, o que explicaria a baixa probabilidade de haver um gatilho espec&#237;fico associado a um substrato card&#237;aco apropriado<sup>4</sup>.</p>
    <p>Como medir, ent&#227;o, a din&#226;mica da instabilidade el&#233;trica? Durante as &#250;ltimas d&#233;cadas, foram realizados diversos estudos em que se testaram formas distintas de medir essa instabilidade el&#233;trica card&#237;aca (ou algum equivalente v&#225;lido) a partir de uma sequ&#234;ncia de batimentos de ECG. Tais estudos, de modo geral, utilizaram duas abordagens principais: 1) quantificar como a vari&#225;vel medida estaria relacionada &#224; propens&#227;o a arritmias futuras, e 2) avaliar com que rapidez o mioc&#225;rdio recomp&#245;e-se ap&#243;s uma arritmia el&#233;trica pequena (por exemplo, extrass&#237;stole) e as consequ&#234;ncias disso sobre o progn&#243;stico futuro.</p>
    <p>Essas abordagens s&#227;o semelhantes &#224; primeira vista, mas tal conclus&#227;o n&#227;o &#233; real. Com base no vocabul&#225;rio usual de arritmias cl&#237;nicas, no qual preven&#231;&#227;o prim&#225;ria e secund&#225;ria significam, respectivamente, preven&#231;&#227;o antes e depois de um evento cardiovascular, poder&#237;amos chamar a primeira de uma <italic>instabilidade prim&#225;ria a arritmias</italic> e a &#250;ltima de uma <italic>instabilidade secund&#225;ria a arritmias</italic>. Entre as medidas cl&#237;nicas de instabilidade prim&#225;ria, poder&#237;amos enumerar o prolongamento do QT, dispers&#227;o do QT, Potenciais Tardios e Micro-altern&#226;ncia da Onda T (<italic>T-wave Alternans - TWA</italic>). Turbul&#234;ncia da Frequ&#234;ncia Card&#237;aca, por outro lado, seria uma medida do grupo de instabilidade secund&#225;ria.</p>
    <p>Esta revis&#227;o ir&#225; ressaltar o papel da TWA no panorama atual da estratifica&#231;&#227;o de risco card&#237;aco. Devido &#224; vasta literatura sobre o t&#243;pico, esta revis&#227;o se dividir&#225; em quatro partes. Ap&#243;s definir TWA e fazer um hist&#243;rico resumido da mesma, ser&#225; retratado na segunda parte o desempenho progn&#243;stico dela em diferentes popula&#231;&#245;es. Uma vez que a TWA &#233; um exame que depende essencialmente de tecnologia, a terceira se&#231;&#227;o tecer&#225; considera&#231;&#245;es sobre um aspecto crucial para o desempenho cl&#237;nico da TWA: as abordagens tecnol&#243;gicas dispon&#237;veis e suas consequentes op&#231;&#245;es de an&#225;lise e limita&#231;&#245;es. A quarta parte explorar&#225; outros fatores que podem modular os valores e influenciar os exames de TWA.</p>
    <p>
      <bold>Defini&#231;&#227;o de TWA e hist&#243;rico resumido</bold>
    </p>
    <p>A chamada TWA &#233; uma oscila&#231;&#227;o de amplitude regular na por&#231;&#227;o ST-T do tra&#231;ado de ECG que ocorre com metade da frequ&#234;ncia card&#237;aca. Em outras palavras, as altera&#231;&#245;es de amplitude do ST-T se repetem a cada duas batidas, de forma que possa ser criado um padr&#227;o de amplitude com batimentos pares e outro com batimentos &#237;mpares. Para fins did&#225;ticos, podemos resumir a hist&#243;ria cronol&#243;gica da pesquisa de TWA em tr&#234;s fases distintas: a transi&#231;&#227;o do foco da pesquisa, da TWA macrosc&#243;pica para a TWA microsc&#243;pica; o impacto da TWA em microvolts nos protocolos de estratifica&#231;&#227;o de risco e nas pol&#237;ticas de sa&#250;de; e o estabelecimento de uma base experimental s&#243;lida para as atuais descobertas cl&#237;nicas sobre a TWA.</p>
    <p>A TWA macrosc&#243;pica (visual) vem sendo relatada desde os prim&#243;rdios da eletrocardiologia<sup>5</sup>, associada sempre a um progn&#243;stico ruim e considerada um achado raro, at&#233; a primeira publica&#231;&#227;o da descoberta da TWA invis&#237;vel (microsc&#243;pica) na d&#233;cada de 1980<sup>6</sup>. Desde ent&#227;o, diversos grupos t&#234;m estudado a TWA, cada um &#224; sua maneira. Uma consequ&#234;ncia direta disso foi a revis&#227;o publicada em 2005, listando mais de 10 diferentes tecnologias para sua avalia&#231;&#227;o<sup>7</sup>, por&#233;m seus resultados ainda ficavam restritos a segmentos particulares da comunidade de pesquisa cardiol&#243;gica. O passo seguinte - quando a TWA obteve a aten&#231;&#227;o dos cardiologistas cl&#237;nicos, al&#233;m dos pesquisadores em cardiologia - aconteceu no in&#237;cio do s&#233;culo XXI, com a publica&#231;&#227;o de evid&#234;ncias de que a TWA conseguiria reduzir o n&#250;mero m&#233;dio de desfibriladores autom&#225;ticos implant&#225;veis (CDI) necess&#225;rios para conseguir de fato salvar uma vida<sup>8</sup>.</p>
    <p>&#192;quela altura, a altern&#226;ncia da dura&#231;&#227;o do potencial de a&#231;&#227;o intracard&#237;aco (APD-alternans) tamb&#233;m vinha sendo intensamente estudada ao longo dos anos. J&#225; em 2002, foram obtidas evid&#234;ncias de que a APD-alternans era o primeiro elo numa progress&#227;o ordenada de padr&#245;es de oscila&#231;&#227;o de amplitude cada vez mais complexos, at&#233; uma fibrila&#231;&#227;o ventricular (FV) durante uma isquemia<sup>9</sup>, e tamb&#233;m de que APD-alternans atriais foram registradas, consistentemente, antes da transi&#231;&#227;o de um flutter atrial para uma fibrila&#231;&#227;o atrial<sup>10</sup>. Al&#233;m disso, descobriu-se que a altern&#226;ncia da TWA e do APD estavam associadas uma &#224; outra em estudos experimentais<sup>11</sup>, mas at&#233; ent&#227;o n&#227;o havia evid&#234;ncia de que essa rela&#231;&#227;o se mantinha mesmo em contextos cl&#237;nicos.</p>
    <p>A terceira fase da pesquisa de TWA iniciou-se com a solu&#231;&#227;o desse quebra-cabe&#231;as cl&#237;nico. Primeiro, demonstrou-se que pacientes com cardiomiopatia e TV induz&#237;vel ou teste positivo de TWA tinham repolariza&#231;&#227;o mais heterog&#234;nea (tanto no epic&#225;rdio quanto no endoc&#225;rdio) que aqueles sem TV induz&#237;vel ou teste negativo de TWA<sup>12</sup> . Mais tarde, a TWA foi relacionada de forma consistente &#224; APD-alternans endoc&#225;rdica e epic&#225;rdica, de forma que era sempre necess&#225;rio um n&#250;mero m&#237;nimo de locais com APD-alternans para que a TWA fosse medida com sucesso na superf&#237;cie do corpo, por&#233;m as APD-alternans sozinhas nem sempre estavam relacionadas &#224; TWA na superf&#237;cie corporal<sup>13</sup>.</p>
    <p>Atualmente, a TWA apresenta-se como um equivalente cl&#237;nico v&#225;lido da <italic>APD-alternans</italic>, esta, por sua vez, um importante marcador de instabilidade el&#233;trica card&#237;aca. O leitor interessado pode se referir a diversas publica&#231;&#245;es sobre os mecanismos da g&#234;nese da APD-alternans e sua rela&#231;&#227;o com o substrato card&#237;aco arritmog&#234;nico<sup>4,14-17</sup>. Esses fundamentos experimentais agregam valor ao desempenho da estratifica&#231;&#227;o pela TWA em diferentes popula&#231;&#245;es cl&#237;nicas, revistos na se&#231;&#227;o seguinte.</p>
    <p>
      <bold>TWA e estratifica&#231;&#227;o de risco card&#237;aco</bold>
    </p>
    <p>
      <bold>Doen&#231;as card&#237;acas coronarianas ou isqu&#234;micas</bold>
    </p>
    <p>O segundo <italic>Multicenter Automatic Defibrillator Implantation Trial</italic> (Estudo Multic&#234;ntrico sobre Implanta&#231;&#227;o de Desfibrilador Autom&#225;tico Implant&#225;vel) - MADIT-2 trouxe evid&#234;ncias convincentes sobre uma redu&#231;&#227;o da mortalidade com uso do CDI. Seus achados mostraram uma redu&#231;&#227;o global de 31% no risco de mortalidade em pacientes p&#243;s-infartados com fra&#231;&#227;o de eje&#231;&#227;o ventricular esquerda (FEVE) <underline>&lt;</underline> 30%, n&#227;o importando se os pacientes estavam em est&#225;gios mais avan&#231;ados da doen&#231;a, assim definidos atrav&#233;s da classe funcional NYHA e n&#237;vel de nitrog&#234;nio ur&#233;ia no sangue (redu&#231;&#227;o de 28-35%, independente do risco basal de mortalidade nos subgrupos)<sup>18</sup>.</p>
    <p>Em 2003, os <italic>American Centers for Medicare and Medicaid Services</italic> (Centros Americanos de Servi&#231;osda Medicare e Medicaid) - CMS decidiram cobrir os custos do tratamento profil&#225;tico com CDI para pacientes do tipo MADIT-2 e dura&#231;&#227;o do QRS &gt; 120 ms. Em 2005, os CMS expandiram a cobertura para todos os pacientes do tipo MADIT-2<sup>19</sup>, mas ainda havia preocupa&#231;&#227;o com o custo-benef&#237;cio dessa decis&#227;o e a necessidade de uma melhor estratifica&#231;&#227;o de risco<sup>20</sup>.</p>
    <p>A avalia&#231;&#227;o da TWA em 177 pacientes do tipo MADIT-2 resultou em melhor desempenho da estratifica&#231;&#227;o de risco que o da dura&#231;&#227;o do QRS. Pacientes com QRS estreito (QRS &lt; 120 ms) n&#227;o estavam livres do risco de arritmias ventriculares sustentadas (TVS) durante seguimento de 2 anos (taxa de mortalidade = 14%, semelhante &#224; do MADIT-2). Por outro lado, o grupo de pacientes com TWA normal registrou apenas 2 mortes no mesmo per&#237;odo (taxa atuarial de mortalidade de 3,8%), enquanto o conjunto com TWA anormal teve uma HR (hazard ratio) de 4,8 (P = 0,012) para mortalidade por qualquer causa, ajustada para a dura&#231;&#227;o do QRS. No MADIT-2 foram necess&#225;rios 18 CDIs implantados para salvar uma vida, por&#233;m, com a estrat&#233;gia de realiza&#231;&#227;o de exames de TWA, foram necess&#225;rios apenas 7 CDIs para salvar 1 vida<sup>8</sup>.</p>
    <p>Um estudo de coorte prospectivo englobando 768 pacientes isqu&#234;micos com FEVE <underline>&lt;</underline> 35% e sem TV sustentada anterior (51% receberam CDIs), trouxe evid&#234;ncias fortes de que os benef&#237;cios do CDI diferem de acordo com o n&#237;vel de TWA, diminuindo a mortalidade por qualquer causa (HR = 0,45, 95% CI = [0,27, 076], P = 0,003) dos pacientes com TWA n&#227;o negativa (positiva ou indeterminada), mas sem redu&#231;&#227;o da mortalidade no grupo com TWA negativa (HR = 0,85, 95% CI = [0,33, 2,20], P = 0,73). Al&#233;m disso, tamb&#233;m foi demonstrado que tais achados se deveram em grande parte &#224; redu&#231;&#227;o da mortalidade arr&#237;tmica. Com rela&#231;&#227;o &#224; efic&#225;cia da terapia por CDI, foram necess&#225;rios 9 CDIs para salvar 1 vida em um per&#237;odo de 2 anos nos pacientes com TWA n&#227;o negativa, por&#233;m foram necess&#225;rios 76 CDIs para salvar 1 vida, no mesmo per&#237;odo, no grupo com TWA negativa<sup>21</sup>.</p>
    <p>
      <bold>Ap&#243;s infarto agudo do mioc&#225;rdio</bold>
    </p>
    <p>Com rela&#231;&#227;o &#224; capacidade de prever eventos arr&#237;tmicos s&#233;rios, no contexto de uma fun&#231;&#227;o card&#237;aca preservada ap&#243;s infarto agudo do mioc&#225;rdio (IAM), um estudo prospectivo japon&#234;s (n = 1.041; 79% homens) descobriu que a TWA mostrou um desempenho progn&#243;stico semelhante a estudos em popula&#231;&#245;es p&#243;s-IAM com FEVE deprimida. Os testes de TWA foram realizados no m&#237;nimo 14 dias p&#243;s-IAM, com 169 (17%) testes positivos, 747 (74%) negativos e 87 (9%) testes indeterminados, sensibilidade geral e valor preditivo negativo de 81% e 99,6%, respectivamente, e em an&#225;lise multivariada HR = 19,7 - 95% CI = (5,5-70,4), P &lt; 0,0001 para eventos arr&#237;tmicos<sup>22</sup>.</p>
    <p>O estudo REFINE (<italic>Risk Estimation Following Infarction, Noninvasive Evaluation</italic> - Estimativa de Risco Ap&#243;s Infarto, Avalia&#231;&#227;o N&#227;o Invasiva) avaliou o desempenho progn&#243;stico do exame de t&#244;nus auton&#244;mico e/ou substrato el&#233;trico card&#237;aco na identifica&#231;&#227;o de pacientes com risco card&#237;aco mais alto logo ap&#243;s IAM.</p>
    <p>Resumindo, nenhum par&#226;metro isolado (TWA, turbul&#234;ncia da frequ&#234;ncia card&#237;aca, sensibilidade barorreflexa), em avalia&#231;&#227;o realizada 2 a 4 semanas (fase aguda) ap&#243;s IAM, predisse resultados com sucesso. A melhor precis&#227;o diagn&#243;stica na fase n&#227;o aguda (10 a 14 semanas) ap&#243;s IAM foi obtida combinando TWA anormal e turbul&#234;ncia da FC, mais FEVE &lt; 50%. Esse indicador composto identificou corretamente dois ter&#231;os de todos os pacientes que sofreram um ataque card&#237;aco, com sensibilidade de 55%, especificidade de 86% e valor preditivo negativo de 96%. &#201; importante notar que a TWA medida durante stress por exerc&#237;cio ou em registros de Holter apresentou desempenho semelhante, embora ela tivesse sido avaliada em cada caso com uma tecnologia diferente.</p>
    <p>Em uma an&#225;lise multivariada ajustada para idade, sexo, IAM anterior e diabete, o indicador composto por Holter e TWA resultou em HR = 6,22 - 95% CI = (2,88 - 13,47), P &lt; 0,001, e a composi&#231;&#227;o com TWA de exerc&#237;cio produziu HR = 5,08 - 95% CI = (2,17 - 11,89), P &lt; 0,001<sup>23</sup>.</p>
    <p>Diferente dos achados do REFINE, outro estudo sobre avalia&#231;&#227;o da TWA no per&#237;odo de 7 a 30 dias ap&#243;s IAM (n = 119) resultou em 17 (14%) testes indeterminados, 50 (42%) testes positivos, e 52 (44%) testes negativos. Em um per&#237;odo de seguimento de 3 a 23 meses, a TWA teve o melhor valor progn&#243;stico entre os indicadores (TWA, potenciais tardios, fra&#231;&#227;o de eje&#231;&#227;o): 14 dos 15 pacientes com eventos arr&#237;tmicos tiveram TWA positiva, com a melhor sensibilidade e valor preditivo negativo entre todos os par&#226;metros analisados (93% e 98%, respectivamente; chance relativa (<italic>relative hazard</italic>) de 16,8, P = 0,006)<sup>24</sup>.</p>
    <p>A TWA se mostrou muito eficiente como estratificador de risco nos pacientes p&#243;s-infarto do mioc&#225;rdio com FEVE <underline>&lt;</underline> 30%, independente o est&#225;gio da doen&#231;a. Desta forma, como m&#233;todo n&#227;o invasivo, pode ser uma ferramenta importante na avalia&#231;&#227;o dos pacientes portadores de doen&#231;a isqu&#234;mica.</p>
    <p>
      <bold>Indiv&#237;duos aparentemente saud&#225;veis e popula&#231;&#227;o em geral</bold>
    </p>
    <p>
      <bold>Adultos</bold>
    </p>
    <p>A preval&#234;ncia de TWA foi avaliada em repouso e durante o exerc&#237;cio em sujeitos aparentemente saud&#225;veis (nenhum com medica&#231;&#227;o permanente), em um total de 48 indiv&#237;duos (idades 21-53 anos, 29 homens). Foram exclu&#237;das doen&#231;as card&#237;acas funcionais e estruturais atrav&#233;s do hist&#243;rico cl&#237;nico e de avalia&#231;&#227;o por ECG de repouso e exerc&#237;cio, e ecocardiografia Doppler. Surtos transit&#243;rios de TWA foram observados em 5 (10,4%) indiv&#237;duos. Foi registrada TWA sustentada em 2 (4,2%) sujeitos, por&#233;m apenas 1 (2,1%) se enquadrou em todos os crit&#233;rios de positividade, e nenhum dos 48 indiv&#237;duos desenvolveu morbidade por arritmia durante o seguimento de 12-40 meses<sup>25</sup>. Um estudo mais amplo (110 sujeitos saud&#225;veis, 20-75 anos, 76 homens) foi publicado no mesmo ano, com 5 (5%) sujeitos que tiveram teste positivo de TWA, 98 (89%) indiv&#237;duos com TWA negativa, e 7 (6%) com teste indeterminado de TWA. Novamente, n&#227;o foi registrada nenhuma morbidade ou mortalidade por arritmia durante seguimento de 32 &#177; 15 meses<sup>26</sup>.</p>
    <p>
      <bold>Abaixo de 18</bold>
    </p>
    <p>A TWA foi avaliada em 100 volunt&#225;rios normais (8-17 anos, sem hist&#243;ria de doen&#231;a card&#237;aca, com exames cl&#237;nicos e ECG de repouso normais). O ru&#237;do excessivo prejudicou o registro adequado de dados durante o exerc&#237;cio de 16 volunt&#225;rios e o repouso de outros 24 volunt&#225;rios, por&#233;m todos os outros 76 volunt&#225;rios tiveram TWA negativa em repouso. Nove volunt&#225;rios (11% dos testes v&#225;lidos) tiveram altern&#226;ncia sustentada, todos com frequ&#234;ncias card&#237;acas iniciais mais altas que os crit&#233;rios adultos usuais: eles tiveram varia&#231;&#227;o de 120 a 158 bpm, enquanto o limiar usual de frequ&#234;ncia card&#237;aca inicial &#233; menor ou igual a 110 bpm<sup>27</sup>.</p>
    <p>
      <bold>Popula&#231;&#227;o em geral</bold>
    </p>
    <p>Um subestudo do FINCAVAS (<italic>Finnish Cardiovascular Study</italic>) descreveu a avalia&#231;&#227;o da TWA em uma coorte de 1.037 pacientes (61,4% homens, 58 &#177; 13 anos), extra&#237;da de uma popula&#231;&#227;o geral, todos encaminhados para teste de stress por exerc&#237;cio. As indica&#231;&#245;es cl&#237;nicas para o teste de exerc&#237;cio inclu&#237;am diagn&#243;stico de doen&#231;a card&#237;aca coronariana (46%), vulnerabilidade a arritmia induzida por exerc&#237;cio (18%), avalia&#231;&#227;o de capacidade de trabalho card&#237;aco (19%), adequa&#231;&#227;o do tratamento para doen&#231;a card&#237;aca coronariana (24%), levantamento de perfil de paciente antes de opera&#231;&#227;o invasiva (13%) e avalia&#231;&#227;o ap&#243;s infarto do mioc&#225;rdio (10%). A TWA induzida por exerc&#237;cio, com ponto de corte em 47 <italic>&#181;</italic>V ou 65 <italic>&#181;</italic>V, foi fortemente preditora de MSC (RR = 2,9, P = 0,02 e RR = 7,4, P &lt; 0,001, respectivamente), bem como de morte cardiovascular (RR = 2,6, P = 0,01 e RR = 6,0, P &lt; 0,001), produzindo excelentes valores preditivos negativos, ambos pr&#243;ximos de 98%<sup>28</sup>.</p>
    <p>
      <bold>Atletas</bold>
    </p>
    <p>Jogadores de futebol amadores com e sem prolapso de valva mitral e sujeitos sedent&#225;rios, pareados por idade (tr&#234;s grupos de 20 indiv&#237;duos), n&#227;o tiveram qualquer teste positivo de TWA em protocolos normais de stress por exerc&#237;cio<sup>29</sup>. TWA e EEF tamb&#233;m foram realizados em atletas de competi&#231;&#227;o profissionais, de diversos esportes, tanto saud&#225;veis (n = 48) quanto com arritmias importantes, por&#233;m sem patologia arritmog&#234;nica (n = 52). Nenhum atleta saud&#225;vel teve teste positivo ou qualquer evento durante seguimento m&#233;dio de 36 meses.</p>
    <p>Por outro lado, 7 em 52 (13,5%) atletas com arritmias tiveram teste positivo de TWA, 5 dos quais tamb&#233;m tiveram teste positivo de EFF para TV e 1 positivo para taquicardia supraventricular grave (o outro recusou-se a fazer EEF). No grupo de atletas arr&#237;tmicos, todos os 42 testes negativos de TWA foram tamb&#233;m acompanhados por EEF negativa, com exce&#231;&#227;o de um, especificamente em tratamento com amiodarona. Entretanto, este sujeito com TWA negativa/EEF positiva n&#227;o teve nenhum evento durante seguimento de 25,3 meses<sup>30</sup>.</p>
    <p>Estudo recente em atletas com arritmias ventriculares (n= 85, 61 homens) enfatizou a boa correla&#231;&#227;o entre resultados de TWA e EEF nessa popula&#231;&#227;o. N&#250;meros semelhantes foram descritos para testes positivos de TWA (15 em 85, 18%), com menor frequ&#234;ncia de testes negativos de TWA (57/85, 68%) e mais testes indeterminados (13/85, 14%). Todos os atletas com TWA positiva tiveram resultado de EEF positivo e todos os atletas com TWA negativa tiveram resultado de EEF negativo. N&#227;o se encontrou qualquer correla&#231;&#227;o entre resultados indeterminados de TWA e EEF. Com rela&#231;&#227;o &#224; ocorr&#234;ncia de eventos, atletas com TWA negativa n&#227;o tiveram nenhum evento durante seguimento m&#233;dio de 30 meses, por&#233;m 5 sujeitos com TWA positiva, bem como 2 sujeitos com TWA indeterminada, relataram eventos nesse prazo<sup>31</sup>.</p>
    <p>A TWA poder&#225; se tornar um bom estratificador de risco em indiv&#237;duos normais, por&#233;m ainda s&#227;o necess&#225;rios estudos mais aprofundados, com amostras de tamanhos adequados, para que se possa contar com dados confi&#225;veis a respeito destas popula&#231;&#245;es.</p>
    <p>
      <bold>Metodologias anal&#237;ticas de TWA</bold>
    </p>
    <p>A TWA &#233; um exame que depende essencialmente da tecnologia usada, uma vez que as oscila&#231;&#245;es t&#237;picas de sua amplitude (com magnitude da ordem de poucos 1/50 mm em ganho normal de 10 mm/mV) est&#227;o al&#233;m da resolu&#231;&#227;o visual do m&#233;dico. Como mencionado no hist&#243;rico, h&#225; diversas metodologias distintas de avalia&#231;&#227;o da TWA. Assim, a escolha da metodologia ter&#225; um impacto direto sobre os valores medidos e as limita&#231;&#245;es cl&#237;nicas da TWA, mesmo que os diferentes algoritmos de TWA tenham desempenho cl&#237;nico semelhante<sup>23,32</sup>. Esta se&#231;&#227;o tem a inten&#231;&#227;o de resumir os conceitos b&#225;sicos, al&#233;m de distinguir as caracter&#237;sticas e as limita&#231;&#245;es cl&#237;nicas das mais relevantes metodologias desenvolvidas para an&#225;lise de TWA. Desta forma, foram considerados relevantes os dois &#250;nicos algoritmos de an&#225;lise de TWA dispon&#237;veis comercialmente (m&#233;todo espectral e m&#233;dia modificada m&#243;vel) e as mais semelhantes metodologias de pesquisa (demodula&#231;&#227;o complexa e m&#233;dia intra-batimentos).</p>
    <p>
      <bold>Como &#233; medida a TWA?</bold>
    </p>
    <p>Relembrando a defini&#231;&#227;o de TWA, o conceito b&#225;sico &#233; a frequ&#234;ncia. Quando presente, a TWA ocorre sempre na metade da frequ&#234;ncia card&#237;aca ou, em outras palavras, a uma frequ&#234;ncia de 0,5 ciclo por batimento (cpb). Sempre que pensamos em detec&#231;&#227;o autom&#225;tica de TWA, esta &#233; a &#250;nica informa&#231;&#227;o dispon&#237;vel <italic>a priori</italic>, uma vez que ningu&#233;m sabe de antem&#227;o se ela estar&#225; presente ou n&#227;o, ou qual parte do complexo ST-T se alternar&#225;, ou mesmo que magnitude ter&#225; a altern&#226;ncia registrada. &#201; bem parecido com sintonizarmos uma esta&#231;&#227;o num r&#225;dio est&#233;reo de carro: sabemos a frequ&#234;ncia de r&#225;dio que interessa, mas n&#227;o podemos predizer se haver&#225; qualquer informa&#231;&#227;o relevante nela, ou apenas ru&#237;do.</p>
    <p>A partir dessa caracter&#237;stica distintiva da TWA - frequ&#234;ncia fixa - pareceu bastante l&#243;gico (ou natural) que as primeiras formas de an&#225;lise de TWA tenham se baseado no rastreamento dessa frequ&#234;ncia de 0,5 cpb. Essa abordagem atualmente &#233; encontrada no m&#233;todo espectral (SM) e na demodula&#231;&#227;o complexa (CD).</p>
    <p>
      <bold>M&#233;todo espectral (SM - <italic>spectral method</italic>)</bold>
    </p>
    <p>O SM mede flutua&#231;&#245;es da onda T atrav&#233;s da computa&#231;&#227;o de diferen&#231;as ponto a ponto entre 128 locais equidistantes no ST-T numa s&#233;rie de 128 batimentos consecutivos alinhados (j&#225; descartados os batimentos ect&#243;picos e com ru&#237;do)<sup>33</sup>. Em outras palavras, h&#225; 128 tacogramas semelhantes &#224;queles usados na an&#225;lise da variabilidade da frequ&#234;ncia card&#237;aca. Depois, s&#227;o computados 128 espectros de frequ&#234;ncia (da&#237; o nome da metodologia - SM), sendo calculada a m&#233;dia deles. O valor da TWA &#233; ent&#227;o avaliado na frequ&#234;ncia de 0,5 cpb (<xref ref-type="fig" rid="f01">Fig.1</xref>). Em 1994, foi publicada pela primeira vez a adapta&#231;&#227;o dessa t&#233;cnica a pacientes humanos<sup>34</sup>. Desde ent&#227;o, ela &#233; o m&#233;todo de an&#225;lise de TWA mais usado, com a mais ampla gama de aplica&#231;&#245;es.</p>
    <p content-type="asset">
      <fig id="f01">
        <graphic xlink:href="1678-4170-abc-96-03-0e53-00018-gf01.jpg"/></fig>
    </p>
    <p>
      <bold>Demodula&#231;&#227;o complexa (CD - <italic>complex demodulation</italic>)</bold>
    </p>
    <p>O m&#233;todo CD foi apresentado mais tarde que o SM<sup>36</sup>, como um algoritmo alternativo. Basicamente este m&#233;todo avalia somente a energia na vizinhan&#231;a pr&#243;xima da frequ&#234;ncia de altern&#226;ncias de 0,5 cpb, ao inv&#233;s de calcular as flutua&#231;&#245;es ao longo de uma ampla faixa de frequ&#234;ncias, como faz o SM.</p>
    <p>&#192; medida que o campo de pesquisa de TWA amadureceu, uma nova fam&#237;lia de algoritmos surgiu, todos baseados na compara&#231;&#227;o de padr&#245;es de batimentos. Essa abordagem atualmente &#233; encontrada na m&#233;dia modificada m&#243;vel (MMA) e na m&#233;dia intra-batimentos.</p>
    <p>
      <bold>M&#233;dia modificada m&#243;vel (MMA - <italic>modified moving average</italic>)</bold>
    </p>
    <p>A MMA cria, recursivamente, dois padr&#245;es (modelos) de batimentos, a partir de qualquer sequ&#234;ncia de batimentos v&#225;lidos (sendo um padr&#227;o associado somente aos batimentos pares, e o outro aos batimentos &#237;mpares). Para explicitar cada um dos padr&#245;es de batimentos o algoritmo iterativo &#233; o seguinte: as diferen&#231;as de amplitude entre o padr&#227;o atual (de batimentos pares ou &#237;mpares) e o pr&#243;ximo batimento v&#225;lido (par ou &#237;mpar) s&#227;o medidas ao longo de diversos locais equidistantes no ST-T. Cada uma dessas diferen&#231;as &#233; dividida em X partes iguais (onde X pode ser 8, 16, 32 ou 64) e a contribui&#231;&#227;o do batimento atual v&#225;lido na atualiza&#231;&#227;o do batimento-padr&#227;o &#233; ent&#227;o limitada a 1/X (chamado de fator de atualiza&#231;&#227;o ou fra&#231;&#227;o limitante) das diferen&#231;as entre modelo e batimento (<xref ref-type="fig" rid="f2">Fig.2</xref>). Finalmente, os valores da TWA s&#227;o disponibilizados a cada 15 segundos, como a diferen&#231;a entre os dois padr&#245;es representativos (e continuamente atualizados) dos batimentos pares e batimentos &#237;mpares<sup>37</sup>.</p>
    <fig id="f2">
      <graphic xlink:href="1678-4170-abc-96-03-0e53-00018-gf02.jpg"/></fig>
    <p>
      <bold>M&#233;dia intra-batimentos (IBA - <italic>intrabeat average</italic>)</bold>
    </p>
    <p>O conceito e as caracter&#237;sticas da m&#233;dia intra-batimentos (IBA) s&#227;o muito semelhantes &#224;queles apresentados no m&#233;todo MMA. Sua marca distintiva &#233; a reparti&#231;&#227;o do complexo ST-T em tr&#234;s intervalos de tempo (T-inicial a T-pico - que inclui o segmento ST; T-pico a T-final; T-inicial a T-final) e a computa&#231;&#227;o de valores distintos da TWA para cada um deles<sup>39-41</sup>.</p>
    <p>
      <bold>Fatores que modulam a TWA</bold>
    </p>
    <p>
      <bold>Altera&#231;&#245;es fisiol&#243;gicas e patofisiol&#243;gicas</bold>
    </p>
    <p>Achados iniciais obtidos em estudos de Holter afirmaram que a magnitude da TWA responde a flutua&#231;&#245;es circadianas e altera&#231;&#245;es fisiol&#243;gicas<sup>40,42,43</sup>. An&#225;lises multivariadas de ECGs ambulatoriais de 24 horas, registrados em pacientes da base de dados do ensaio ATRAMI (<italic>Autonomic Tone and Reflexes After Myocardial Infarction</italic> - T&#244;nus Auton&#244;mico e Reflexos Ap&#243;s Infarto do Mioc&#225;rdio), apontaram que n&#237;veis de TWA acima do percentil 75 &#224;s 8:00 h da manh&#227;, ou na frequ&#234;ncia card&#237;aca m&#225;xima (cerca de 47 <italic>&#181;</italic>V) foram relacionados a chances mais altas de ataque card&#237;aco (FV documentada) ou de morte arr&#237;tmica durante o per&#237;odo de seguimento (OR variou de 4,2 a 7,9, dependendo da deriva&#231;&#227;o [eletrodo] e do per&#237;odo de tempo)<sup>38</sup>. Mais tarde, Stein e cols.<sup>44</sup> notaram que, na m&#233;dia, os n&#237;veis mais altos de TWA acompanharam o ciclo circadiano de aumento de risco de morte s&#250;bita em pacientes com insufici&#234;ncia card&#237;aca. Al&#233;m disso, descobriu-se que n&#237;veis de TWA acima de 47 <italic>&#181;</italic>V est&#227;o associados a risco aumentado de MSC.</p>
    <p>Sobre processos patol&#243;gicos que afetam a magnitude de TWA, Shusterman e cols.<sup>40</sup> demonstraram um aumento na magnitude de TWA precedendo o in&#237;cio espont&#226;neo de taquiarritmias ventriculares (TAV). Registros de Holter (n=59) com TAV espont&#226;nea foram selecionados do banco de dados do ensaio cl&#237;nico ESVEM (<italic>Electrophysiologic Study Versus Electrocardiographic Monitoring</italic> - Estudo Eletrofisiol&#243;gico versus Monitoramento Eletrocardiogr&#225;fico). Seus resultados mostram que a magnitude da TWA aumentou continuamente da linha basal at&#233; um pico de 25%, 10 minutos antes do evento. Pesquisadores do estudo TOVA (<italic>Triggers of Ventricular Arrhythmias</italic> - Deflagradores de Arritmias Ventriculares) tamb&#233;m verificaram a exist&#234;ncia de magnitude de TWA significante antes do in&#237;cio de arritmia, usando eletrogramas<sup>45</sup>. Tamb&#233;m foram registradas altera&#231;&#245;es temporais de TWA p&#243;s-infarto durante os primeiros 6 meses ap&#243;s o evento, provavelmente ap&#243;s remodelamento ventricular depois de infarto agudo do mioc&#225;rdio<sup>46</sup>. Eventualmente, a TWA em n&#237;veis patol&#243;gicos foi fortemente associada &#224; denerva&#231;&#227;o simp&#225;tica card&#237;aca e &#224; atividade nervosa simp&#225;tica acelerada em pacientes com cardiomiopatia idiop&#225;tica dilatada, em avalia&#231;&#227;o por exame com Iodo-123 (I-123) metaiodobenzilguanidina (MIBG) e ecocardiograma<sup>47</sup>.</p>
    <p>Outros estudos investigaram os efeitos de stress mental agudo (por recapitula&#231;&#227;o de lembran&#231;as que induziram raiva ou por aritm&#233;tica mental) sobre a TWA. Kop e cols.<sup>43</sup> conclu&#237;ram que isso aumenta a amplitude da TWA em pacientes com CDI, com doen&#231;a arterial coronariana documentada (n = 23), em frequ&#234;ncias card&#237;acas mais baixas que as dos protocolos de exerc&#237;cio usados atualmente na avalia&#231;&#227;o de TWA<sup>43</sup>. Lampert e cols.<sup>48</sup> n&#227;o somente registraram TWA aumentada devido a stress mental em pacientes com CDI (n = 33), mas tamb&#233;m descobriu que as altera&#231;&#245;es da TWA se correlacionaram bem com altera&#231;&#245;es na frequ&#234;ncia card&#237;aca, press&#227;o arterial sist&#243;lica e catecolaminas<sup>48</sup>, na mesma linha das evid&#234;ncias anteriores de que o stress mental altera tanto o comprimento de ciclo quanto a cessa&#231;&#227;o de TV em pacientes com CDI sem isquemia<sup>49</sup>.</p>
    <p>Finalmente, algumas influ&#234;ncias externas tamb&#233;m podem afetar a TWA. Estimula&#231;&#227;o da medula espinal (SCS) &#233; usada atualmente em pacientes com angina n&#227;o trat&#225;vel e se cogita que ela tenha um efeito antiarr&#237;tmico sobre o substrato arritmog&#234;nico. O estudo dos padr&#245;es de TWA para avaliar altera&#231;&#245;es no substrato arr&#237;tmico indica que pacientes que originalmente tiveram testes positivos de TWA de alta amplitude quando o estimulador estava desligado, experimentaram um rebaixamento dos valores de TWA (por&#233;m ainda com teste positivo de TWA) ap&#243;s 2 horas da SCS. Ap&#243;s 24 horas da SCS, todos os pacientes se tornaram TWA-negativos. Nesta amostra, todos os pacientes estavam j&#225; em pleno tratamento com beta-bloqueadores e nenhuma altera&#231;&#227;o da frequ&#234;ncia card&#237;aca basal ou da condu&#231;&#227;o atrioventricular foi observada em testes consecutivos de TWA. Esses achados sugerem um efeito de remodelamento dependente do tempo sobre o substrato arritmog&#234;nico (avaliado por TWA) independente de remo&#231;&#227;o simp&#225;tica<sup>50</sup>.</p>
    <p>Outra influ&#234;ncia externa - choques de CDI durante teste de desfibrila&#231;&#227;o normal (n = 65 pacientes) - aumentou agudamente a magnitude da TWA, mediada em parte por estimula&#231;&#227;o simp&#225;tica<sup>43</sup>. Al&#233;m disso, s&#227;o necess&#225;rios estudos para demonstrar se esse aumento da TWA pode ser associado ao mecanismo mais comum de morte s&#250;bita em pacientes com CDI<sup>51</sup>, i.e., a dissocia&#231;&#227;o eletromec&#226;nica p&#243;s-choque que se segue a uma TV/FV tratada. Sobre este t&#243;pico, um aspecto chave a ser considerado &#233; que problemas no ciclo celular de c&#225;lcio - j&#225; associados &#224; disfun&#231;&#227;o ventricular mec&#226;nica - s&#227;o fortemente relacionados a <italic>APD-alternans</italic><sup>4,14,15,17</sup>.</p>
    <p>
      <bold>Considera&#231;&#245;es finais</bold>
    </p>
    <p>O papel progn&#243;stico da TWA na estratifica&#231;&#227;o de risco cl&#237;nico &#233; cada vez mais claro, mas ainda comporta algumas controv&#233;rsias. Por um lado, a literatura atualmente dispon&#237;vel apresenta fortes evid&#234;ncias de um bom desempenho progn&#243;stico (notavelmente, seu valor preditivo negativo) em popula&#231;&#245;es cl&#237;nicas espec&#237;ficas, tais como doen&#231;a card&#237;aca isqu&#234;mica, ap&#243;s IAM, cardiomiopatia n&#227;o-isqu&#234;mica. A TWA tamb&#233;m igualaria, ou teria exatid&#227;o progn&#243;stica superior ao EEF em outras popula&#231;&#245;es (por ex., atletas com arritmias). Por outro lado, o valor cl&#237;nico da avalia&#231;&#227;o de TWA ainda &#233; assunto para investiga&#231;&#227;o mais profunda em muitos dos seus aspectos, particularmente: outras popula&#231;&#245;es cl&#237;nicas de relev&#226;ncia (p. ex., Chagas) devem ser estudadas; outros protocolos de estudo (p. ex., compara&#231;&#245;es entre a TWA em Holter e a TWA induzida por esfor&#231;o ou estresse farmacol&#243;gico) devem ser inclu&#237;dos; as tecnicalidades de cada metodologia de medi&#231;&#227;o de TWA devem ser consideradas corretamente nos protocolos cl&#237;nicos a serem delineados.</p>
    <p>Os pr&#243;ximos passos na cria&#231;&#227;o de novos protocolos e aplica&#231;&#245;es, na explora&#231;&#227;o mais profunda das possibilidades cl&#237;nicas da TWA, ou no preenchimento das lacunas atuais na base de conhecimento da TWA, seguem uma dire&#231;&#227;o: m&#233;dicos e pesquisadores devem explorar melhor as caracter&#237;sticas tecnol&#243;gicas das diversas tecnologias dispon&#237;veis para avalia&#231;&#227;o da TWA dispon&#237;veis - cada uma com seus pr&#243;prios pontos fortes e fraquezas - conscientes do fato de que os valores de TWA obtidos respondem a diversos outros fatores al&#233;m de medica&#231;&#245;es.</p>
    <p>
      <bold>Potencial Conflito de Interesses</bold>
    </p>
    <p>Declaro n&#227;o haver conflito de interesses pertinentes.</p>
    <p>
      <bold>Fontes de Financiamento</bold>
    </p>
    <p>O presente estudo n&#227;o teve fontes de financiamento externas.</p>
    <p>
      <bold>Vincula&#231;&#227;o Acad&#234;mica</bold>
    </p>
    <p>N&#227;o h&#225; vincula&#231;&#227;o deste estudo a programas de p&#243;s-gradua&#231;&#227;o.</p>
    <p>
      <fn id="back" fn-type="corresp">
        <p>Correspond&#234;ncia:</p>
        <p> Carlos Alberto Pastore </p>
        <p> Instituto do Cora&#231;&#227;o (InCor) </p>
        <p> Hospital das Cl&#237;nicas da Universidade de S&#227;o Paulo </p>
        <p> Av. Dr. En&#233;as de Carvalho Aguiar, 44 - AB - Cerqueira C&#233;sar </p>
        <p> 05403-000 - S&#227;o Paulo, SP - Brasil </p>
        <p> E-mail: </p>
        <p><email xlink:href="evgarcia@unb.br">evgarcia@unb.br</email>, </p>
        <p>
          <email xlink:href="ecg_pastore@incor.usp.br">ecg_pastore@incor.usp.br</email>
        </p>
      </fn>
    </p>
    <p>Artigo recebido em 19/03/09; revisado recebido em 29/05/09; aceito em 18/03/10.</p>
  </body>
  <back>
    <ref-list>
      <ref id="B1">
        <mixed-citation>1. Rubart D, Zipes    P. Mechanisms of sudden cardiac death. J Clin Invest 2005;115:2305-2315.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Mechanisms of sudden cardiac death</article-title>
          <source>J Clin Invest</source>
          <date>
            <year>2005</year>
          </date>
          <fpage>2305</fpage>
          <lpage>2315</lpage>
          <volume>115</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Rubart</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Zipes</surname>
              <given-names>P</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B2">
        <mixed-citation>2. Fabre A, Sheppard    MN. Sudden adult death syndrome and other nonischaemic causes of sudden cardiac    death. Heart 2006;92:316-320.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Sudden adult death syndrome and other nonischaemic causes of sudden cardiac death</article-title>
          <source>Heart</source>
          <date>
            <year>2006</year>
          </date>
          <fpage>316</fpage>
          <lpage>320</lpage>
          <volume>92</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Fabre</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Sheppard</surname>
              <given-names>MN</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B3">
        <mixed-citation>3. Thompson PD,    Franklin BA, Balady GJ, et al. Exercise and acute cardiovascular events: Placing    the risks into perspective: A scientific statement from the American Heart Association    Council on Nutrition, Physical Activity, and Metabolism and the Council on Clinical    Cardiology - In collaboration with the American College of Sports Medicine.    Circulation 2007;115:2358-2368.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Exercise and acute cardiovascular events: Placing the risks into perspective: A scientific statement from the American Heart Association Council on Nutrition, Physical Activity, and Metabolism and the Council on Clinical Cardiology - In collaboration with the American College of Sports Medicine</article-title>
          <source>Circulation</source>
          <date>
            <year>2007</year>
          </date>
          <fpage>2358</fpage>
          <lpage>2368</lpage>
          <volume>115</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Thompson</surname>
              <given-names>PD</given-names>
            </name>
            <name>
              <surname>Franklin</surname>
              <given-names>BA</given-names>
            </name>
            <name>
              <surname>Balady</surname>
              <given-names>GJ</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B4">
        <mixed-citation>4. Weiss JN, Karma    A, Shiferaw Y, et al. From pulsus to pulseless: The saga of cardiac alternans.    Circ Res 2006;98:1244-1253.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>From pulsus to pulseless: The saga of cardiac alternans</article-title>
          <source>Circ Res</source>
          <date>
            <year>2006</year>
          </date>
          <fpage>1244</fpage>
          <lpage>1253</lpage>
          <volume>98</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Weiss</surname>
              <given-names>JN</given-names>
            </name>
            <name>
              <surname>Karma</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Shiferaw</surname>
              <given-names>Y</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B5">
        <mixed-citation>5. Hering HE. Experimentelle    studien an saugetieren uber das elektrocardiogram. Zeitschrift fur experimentelle    Pathologie und Therapie 1909;7:363-378.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Experimentelle studien an saugetieren uber das elektrocardiogram</article-title>
          <source>Zeitschrift fur experimentelle Pathologie und Therapie</source>
          <date>
            <year>1909</year>
          </date>
          <fpage>363</fpage>
          <lpage>378</lpage>
          <volume>7</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Hering</surname>
              <given-names>HE</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B6">
        <mixed-citation>6. Adam DR, Akselrod    S, Cohen RJ. Estimation of ventricular vulnerability to fibrillation through    T-wave time series analysis. Comput Cardiol 1981;8:307-310.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Estimation of ventricular vulnerability to fibrillation through T-wave time series analysis</article-title>
          <source>Comput Cardiol</source>
          <date>
            <year>1981</year>
          </date>
          <fpage>307</fpage>
          <lpage>310</lpage>
          <volume>8</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Adam</surname>
              <given-names>DR</given-names>
            </name>
            <name>
              <surname>Akselrod</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Cohen</surname>
              <given-names>RJ</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B7">
        <mixed-citation>7. Mart&#237;nez    JP, Olmos S. Methodological principles of T wave alternans analysis: A unified    framework. IEEE Trans Biom Eng 2005;52:599-613.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Methodological principles of T wave alternans analysis: A unified framework</article-title>
          <source>IEEE Trans Biom Eng</source>
          <date>
            <year>2005</year>
          </date>
          <fpage>599</fpage>
          <lpage>613</lpage>
          <volume>52</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Mart&#237;nez</surname>
              <given-names>JP</given-names>
            </name>
            <name>
              <surname>Olmos</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B8">
        <mixed-citation>8. Bloomfield DM,    Steinman RC, Namerow PB, et al. Microvolt T-wave alternans distinguishes between    patients likely and patients not likely to benefit from implanted cardiac defibrillator    therapy: A solution to the multicenter automatic defibrillator implantation    trial (MADIT) II conundrum. Circulation 2004;110:1885-1889.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Microvolt T-wave alternans distinguishes between patients likely and patients not likely to benefit from implanted cardiac defibrillator therapy: A solution to the multicenter automatic defibrillator implantation trial (MADIT) II conundrum</article-title>
          <source>Circulation</source>
          <date>
            <year>2004</year>
          </date>
          <fpage>1885</fpage>
          <lpage>1889</lpage>
          <volume>110</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Bloomfield</surname>
              <given-names>DM</given-names>
            </name>
            <name>
              <surname>Steinman</surname>
              <given-names>RC</given-names>
            </name>
            <name>
              <surname>Namerow</surname>
              <given-names>PB</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B9">
        <mixed-citation>9. Nearing BD,    Verrier RL. Progressive increases in complexity of T-wave oscillations herald    ischemia-induced ventricular fibrillation. Circ Res 2002;91:727-732.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Progressive increases in complexity of T-wave oscillations herald ischemia-induced ventricular fibrillation</article-title>
          <source>Circ Res</source>
          <date>
            <year>2002</year>
          </date>
          <fpage>727</fpage>
          <lpage>732</lpage>
          <volume>91</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Nearing</surname>
              <given-names>BD</given-names>
            </name>
            <name>
              <surname>Verrier</surname>
              <given-names>RL</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B10">
        <mixed-citation>10. Narayan SM,    Bode F, Karasik PL, et al. Alternans of atrial action potentials during atrial    flutter as a precursor to atrial fibrillation. Circulation 2002;106:1968-1973.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Alternans of atrial action potentials during atrial flutter as a precursor to atrial fibrillation</article-title>
          <source>Circulation</source>
          <date>
            <year>2002</year>
          </date>
          <fpage>1968</fpage>
          <lpage>1973</lpage>
          <volume>106</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Narayan</surname>
              <given-names>SM</given-names>
            </name>
            <name>
              <surname>Bode</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Karasik</surname>
              <given-names>PL</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B11">
        <mixed-citation>11. Pastore JM,    Girouard SD, Laurita KR, et al. Mechanism linking T-wave alternans to the genesis    of cardiac fibrillation. Circulation 1999;99:1385-1394.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Mechanism linking T-wave alternans to the genesis of cardiac fibrillation</article-title>
          <source>Circulation</source>
          <date>
            <year>1999</year>
          </date>
          <fpage>1385</fpage>
          <lpage>1394</lpage>
          <volume>99</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Pastore</surname>
              <given-names>JM</given-names>
            </name>
            <name>
              <surname>Girouard</surname>
              <given-names>SD</given-names>
            </name>
            <name>
              <surname>Laurita</surname>
              <given-names>KR</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B12">
        <mixed-citation>12. Chauhan VS,    Downar E, Nanthakumar K, et al. Increased ventricular repolarization heterogeneity    in patients with ventricular arrhythmia vulnerability and cardiomyopathy: A    human in vivo study. Am J Physiol Heart Circ Physiol 2006;290:79-86.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Increased ventricular repolarization heterogeneity in patients with ventricular arrhythmia vulnerability and cardiomyopathy: A human in vivo study</article-title>
          <source>Am J Physiol Heart Circ Physiol</source>
          <date>
            <year>2006</year>
          </date>
          <fpage>79</fpage>
          <lpage>86</lpage>
          <volume>290</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Chauhan</surname>
              <given-names>VS</given-names>
            </name>
            <name>
              <surname>Downar</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Nanthakumar</surname>
              <given-names>K</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B13">
        <mixed-citation>13. Selvaraj RJ,    Picton P, Nanthakumar K, et al. Endocardial and epicardial repolarization alternans    in human cardiomyopathy evidence for spatiotemporal heterogeneity and correlation    with body surface T-wave alternans. J Am Coll Cardiol 2007;49:338-346.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Endocardial and epicardial repolarization alternans in human cardiomyopathy evidence for spatiotemporal heterogeneity and correlation with body surface T-wave alternans</article-title>
          <source>J Am Coll Cardiol</source>
          <date>
            <year>2007</year>
          </date>
          <fpage>338</fpage>
          <lpage>346</lpage>
          <volume>49</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Selvaraj</surname>
              <given-names>RJ</given-names>
            </name>
            <name>
              <surname>Picton</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Nanthakumar</surname>
              <given-names>K</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B14">
        <mixed-citation>14. Wilson LD,    Wan X, Rosenbaum DS. Cellular alternans: A mechanism linking calcium cycling    proteins to cardiac arrhythmogenesis. Ann N Y Acad Sci 2006;1080:216-234.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Cellular alternans: A mechanism linking calcium cycling proteins to cardiac arrhythmogenesis</article-title>
          <source>Ann N Y Acad Sci</source>
          <date>
            <year>2006</year>
          </date>
          <fpage>216</fpage>
          <lpage>234</lpage>
          <volume>1080</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Wilson</surname>
              <given-names>LD</given-names>
            </name>
            <name>
              <surname>Wan</surname>
              <given-names>X</given-names>
            </name>
            <name>
              <surname>Rosenbaum</surname>
              <given-names>DS</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B15">
        <mixed-citation>15. Clusin WT.    Mechanisms of calcium transient and action potential alternans in cardiac cells    and tissues. Am J Physiol Heart Circ Physiol 2008;294:H1-H10.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Mechanisms of calcium transient and action potential alternans in cardiac cells and tissues</article-title>
          <source>Am J Physiol Heart Circ Physiol</source>
          <date>
            <year>2008</year>
          </date>
          <fpage>H1</fpage>
          <lpage>H10</lpage>
          <volume>294</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Clusin</surname>
              <given-names>WT</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B16">
        <mixed-citation>16. Fish JM, Antzelevitch    C. Cellular mechanism and arrhythmogenic potential of T-wave alternans in the    brugada syndrome. J Cardiovasc Electrophysiol 2008;19:301-308.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Cellular mechanism and arrhythmogenic potential of T-wave alternans in the brugada syndrome</article-title>
          <source>J Cardiovasc Electrophysiol</source>
          <date>
            <year>2008</year>
          </date>
          <fpage>301</fpage>
          <lpage>308</lpage>
          <volume>19</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Fish</surname>
              <given-names>JM</given-names>
            </name>
            <name>
              <surname>Antzelevitch</surname>
              <given-names>C</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B17">
        <mixed-citation>17. Hayashi H,    Shiferaw Y, Sato D, et al. Dynamic origin of spatially discordant alternans    in cardiac tissue. Biophys J 2007;92:448-460.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Dynamic origin of spatially discordant alternans in cardiac tissue</article-title>
          <source>Biophys J</source>
          <date>
            <year>2007</year>
          </date>
          <fpage>448</fpage>
          <lpage>460</lpage>
          <volume>92</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Hayashi</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Shiferaw</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Sato</surname>
              <given-names>D</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B18">
        <mixed-citation>18. Zareba W, Piotrowicz    K, McNitt S, et al. Implantable cardioverter-defibrillator efficacy in patients    with heart failure and left ventricular dysfunction (from the MADIT II Population).    Am J Cardiol 2005;95:1487-1491.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Implantable cardioverter-defibrillator efficacy in patients with heart failure and left ventricular dysfunction (from the MADIT II Population)</article-title>
          <source>Am J Cardiol</source>
          <date>
            <year>2005</year>
          </date>
          <fpage>1487</fpage>
          <lpage>1491</lpage>
          <volume>95</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Zareba</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Piotrowicz</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>McNitt</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B19">
        <label>19</label>
        <mixed-citation>19. Centers for Medicare and Medicaid Services. NCD for implantable automatic defibrillators. Publication Number 100-3, Manual Section Number 20-4, Version 3, Implementation Date: Jan 27, 2005. Available at: <ext-link ext-link-type="uri" xlink:href="http://www.cms.hhs.gov/mcd/viewncd.asp?ncdid=20.4&amp;ncdversion=3&amp;basket=ncd%3A20%2E4%3A3%3AImplantable+Automatic+Defibrillators">http://www.cms.hhs.gov/mcd/viewncd.asp?ncdid=20.4&amp;ncdversion=3&amp;basket=ncd%3A20%2E4%3A3%3AImplantable+Automatic+Defibrillators</ext-link>. Accessed March 13, 2007.</mixed-citation>
        <element-citation publication-type="book">
          <source>NCD for implantable automatic defibrillators: Publication Number 100-3, Manual Section Number 20-4, Version 3, Implementation Date: Jan 27, 2005</source>
        </element-citation>
      </ref>
      <ref id="B20">
        <mixed-citation>20. Chan PS, Stein    K, Chow T, et al. Cost-effectiveness of a microvolt T-wave alternans screening    strategy for implantable cardioverter-defibrillator placement in the MADIT-II-eligible    population. J Am Coll Cardiol 2006;48:112-121.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Cost-effectiveness of a microvolt T-wave alternans screening strategy for implantable cardioverter-defibrillator placement in the MADIT-II-eligible population</article-title>
          <source>J Am Coll Cardiol</source>
          <date>
            <year>2006</year>
          </date>
          <fpage>112</fpage>
          <lpage>121</lpage>
          <volume>48</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Chan</surname>
              <given-names>PS</given-names>
            </name>
            <name>
              <surname>Stein</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Chow</surname>
              <given-names>T</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B21">
        <mixed-citation>21. Chow T, Kereiakes    DJ, Bartone C, et al. Microvolt Twave alternans identifies patients with ischemic    cardiomyopathy who benefit from implantable cardioverter defibrillator therapy.    J Am Coll Cardiol 2007;49:50-58.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Microvolt Twave alternans identifies patients with ischemic cardiomyopathy who benefit from implantable cardioverter defibrillator therapy</article-title>
          <source>J Am Coll Cardiol</source>
          <date>
            <year>2007</year>
          </date>
          <fpage>50</fpage>
          <lpage>58</lpage>
          <volume>49</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Chow</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Kereiakes</surname>
              <given-names>DJ</given-names>
            </name>
            <name>
              <surname>Bartone</surname>
              <given-names>C</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B22">
        <mixed-citation>22. Ikeda T, Yoshino    H, Sugi K, et al. Predictive value of microvolt T-wave alternans for sudden    cardiac death in patients with preserved cardiac function after acute myocardial    infarction results of a collaborative cohort study. J Am Coll Cardiol 2006;48:2268-2274.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Predictive value of microvolt T-wave alternans for sudden cardiac death in patients with preserved cardiac function after acute myocardial infarction results of a collaborative cohort study</article-title>
          <source>J Am Coll Cardiol</source>
          <date>
            <year>2006</year>
          </date>
          <fpage>2268</fpage>
          <lpage>2274</lpage>
          <volume>48</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Ikeda</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Yoshino</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Sugi</surname>
              <given-names>K</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B23">
        <mixed-citation>23. Exner DV, Kavanagh    KM, Slawnych MP, et al. Noninvasive risk assessment early after a myocardial    infarction - the refine study. J Am Coll Cardiol 2007;50:2275-2284.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Noninvasive risk assessment early after a myocardial infarction - the refine study</article-title>
          <source>J Am Coll Cardiol</source>
          <date>
            <year>2007</year>
          </date>
          <fpage>2275</fpage>
          <lpage>2284</lpage>
          <volume>50</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Exner</surname>
              <given-names>DV</given-names>
            </name>
            <name>
              <surname>Kavanagh</surname>
              <given-names>KM</given-names>
            </name>
            <name>
              <surname>Slawnych</surname>
              <given-names>MP</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B24">
        <mixed-citation>24. Ikeda T, Sakata    T, Takami M, et al. Combined assessment of T-wave alternans and late potentials    used to predict arrhythmic events after myocardial infarction - a prospective    study. J Am Coll Cardiol 2000;35:722-730.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Combined assessment of T-wave alternans and late potentials used to predict arrhythmic events after myocardial infarction - a prospective study</article-title>
          <source>J Am Coll Cardiol</source>
          <date>
            <year>2000</year>
          </date>
          <fpage>722</fpage>
          <lpage>730</lpage>
          <volume>35</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Ikeda</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Sakata</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Takami</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B25">
        <mixed-citation>25. Weber S, Tillmanns    H, Waldecker B. Prevalence of T wave alternans in healthy subjects. Pacing Clin    Electrophysiol 2003;26[Pt.I]:49-52.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Prevalence of T wave alternans in healthy subjects</article-title>
          <source>Pacing Clin Electrophysiol</source>
          <date>
            <year>2003</year>
          </date>
          <fpage>49</fpage>
          <lpage>52</lpage>
          <volume>26</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Weber</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Tillmanns</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Waldecker</surname>
              <given-names>B</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B26">
        <mixed-citation>26. Grimm W, Liedtke    J, Muller H-H. Prevalence of potential noninvasive arrhythmia risk predictors    in healthy, middleaged persons. Ann Noninv Electrocardiol 2003;8:37-46.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Prevalence of potential noninvasive arrhythmia risk predictors in healthy, middleaged persons</article-title>
          <source>Ann Noninv Electrocardiol</source>
          <date>
            <year>2003</year>
          </date>
          <fpage>37</fpage>
          <lpage>46</lpage>
          <volume>8</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Grimm</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Liedtke</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Muller</surname>
              <given-names>H-H</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B27">
        <mixed-citation>27. Cheung MMH,    Davis AM, Cohen RJ, et al. T wave alternans threshold in normal children. J    Cardiovasc Electrophysiol 2001;12:424-427.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>T wave alternans threshold in normal children</article-title>
          <source>J Cardiovasc Electrophysiol</source>
          <date>
            <year>2001</year>
          </date>
          <fpage>424</fpage>
          <lpage>427</lpage>
          <volume>12</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Cheung</surname>
              <given-names>MMH</given-names>
            </name>
            <name>
              <surname>Davis</surname>
              <given-names>AM</given-names>
            </name>
            <name>
              <surname>Cohen</surname>
              <given-names>RJ</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B28">
        <mixed-citation>28. Nieminen T,    Lehtimaki T, Viik J, et al. T-wave alternans predicts mortality in a population    undergoing a clinically indicated exercise test. Eur Heart J 2007;28:2332-2337.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>T-wave alternans predicts mortality in a population undergoing a clinically indicated exercise test</article-title>
          <source>Eur Heart J</source>
          <date>
            <year>2007</year>
          </date>
          <fpage>2332</fpage>
          <lpage>2337</lpage>
          <volume>28</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Nieminen</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Lehtimaki</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Viik</surname>
              <given-names>J</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B29">
        <mixed-citation>29. Koutlianos    NA, Kouidi EJ, Metaxas TI, et al. Non-invasive cardiac electrophysiological    indices in soccer players with mitral valve prolapse. Eur J Cardiovasc Prev    Rehabil 2004;11:435-441.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Non-invasive cardiac electrophysiological indices in soccer players with mitral valve prolapse</article-title>
          <source>Eur J Cardiovasc Prev Rehabil</source>
          <date>
            <year>2004</year>
          </date>
          <fpage>435</fpage>
          <lpage>441</lpage>
          <volume>11</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Koutlianos</surname>
              <given-names>NA</given-names>
            </name>
            <name>
              <surname>Kouidi</surname>
              <given-names>EJ</given-names>
            </name>
            <name>
              <surname>Metaxas</surname>
              <given-names>TI</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B30">
        <mixed-citation>30. Furlanello    F, Galanti G, Manetti P, et al. Microvolt Twave alternans as predictor of electrophysiological    testing results in professional competitive athletes. Ann Noninv Electrocardiol    2004;9:201-206.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Microvolt Twave alternans as predictor of electrophysiological testing results in professional competitive athletes</article-title>
          <source>Ann Noninv Electrocardiol</source>
          <date>
            <year>2004</year>
          </date>
          <fpage>201</fpage>
          <lpage>206</lpage>
          <volume>9</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Furlanello</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Galanti</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Manetti</surname>
              <given-names>P</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B31">
        <mixed-citation>31. Inama G, Pedrinazzi    C, Durin O, et al. Microvolt T-wave alternans for risk stratification in athletes    with ventricular arrhythmias: Correlation with programmed ventricular stimulation.    Ann Noninv Electrocardiol 2008;13:14-21.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Microvolt T-wave alternans for risk stratification in athletes with ventricular arrhythmias: Correlation with programmed ventricular stimulation</article-title>
          <source>Ann Noninv Electrocardiol</source>
          <date>
            <year>2008</year>
          </date>
          <fpage>14</fpage>
          <lpage>21</lpage>
          <volume>13</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Inama</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Pedrinazzi</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Durin</surname>
              <given-names>O</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B32">
        <mixed-citation>32. Cox V, Patel    M, Kim J, et al. Predicting arrhythmiafree survival using spectral and modified-moving    average analyses of T-wave alternans. Pacin Clin Electrophysiol 2007;30:352-358.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Predicting arrhythmiafree survival using spectral and modified-moving average analyses of T-wave alternans</article-title>
          <source>Pacin Clin Electrophysiol</source>
          <date>
            <year>2007</year>
          </date>
          <fpage>352</fpage>
          <lpage>358</lpage>
          <volume>30</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Cox</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Patel</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Kim</surname>
              <given-names>J</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B33">
        <mixed-citation>33. Smith JM, Clancy    EA, Valeri CR, et al. Electrical alternans and cardiac electrical instability.    Circulation 1988;77:110-121.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Electrical alternans and cardiac electrical instability</article-title>
          <source>Circulation</source>
          <date>
            <year>1988</year>
          </date>
          <fpage>110</fpage>
          <lpage>121</lpage>
          <volume>77</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Smith</surname>
              <given-names>JM</given-names>
            </name>
            <name>
              <surname>Clancy</surname>
              <given-names>EA</given-names>
            </name>
            <name>
              <surname>Valeri</surname>
              <given-names>CR</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B34">
        <mixed-citation>34. Rosenbaum DS,    Jackson LE, Smith JM, et al. Electrical alternans and vulnerability to ventricular    arrhythmias. N Engl J Med 1994;330:235-241.4.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Electrical alternans and vulnerability to ventricular arrhythmias</article-title>
          <source>N Engl J Med</source>
          <date>
            <year>1994</year>
          </date>
          <fpage>235</fpage>
          <lpage>241.4</lpage>
          <volume>330</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Rosenbaum</surname>
              <given-names>DS</given-names>
            </name>
            <name>
              <surname>Jackson</surname>
              <given-names>LE</given-names>
            </name>
            <name>
              <surname>Smith</surname>
              <given-names>JM</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B35">
        <mixed-citation>35. Garcia E de    V. T-wave alternans: reviewing the clinical performance, understanding limitations,    characterizing methodologies. Ann Noninvasive Electrocardiol. 2008; 13 (4):    401-20.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>T-wave alternans: reviewing the clinical performance, understanding limitations, characterizing methodologies</article-title>
          <source>Ann Noninvasive Electrocardiol</source>
          <date>
            <year>2008</year>
          </date>
          <fpage>401</fpage>
          <lpage>20</lpage>
          <issue>4</issue>
          <volume>13</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Garcia E de</surname>
              <given-names>V</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B36">
        <mixed-citation>36. Nearing BD,    Verrier RL. Personal computer system for tracking cardiac vulnerability by complex    demodulation of the T wave. J Appl Physiol 1993;74:2606-2612.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Personal computer system for tracking cardiac vulnerability by complex demodulation of the T wave</article-title>
          <source>J Appl Physiol</source>
          <date>
            <year>1993</year>
          </date>
          <fpage>2606</fpage>
          <lpage>2612</lpage>
          <volume>74</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Nearing</surname>
              <given-names>BD</given-names>
            </name>
            <name>
              <surname>Verrier</surname>
              <given-names>RL</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B37">
        <mixed-citation>37. Nearing BD,    Verrier RL. Modified moving average analysis of T-wave alternans to predict    ventricular fibrillation with high accuracy. J Appl Physiol 2002;92:541-549.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Modified moving average analysis of T-wave alternans to predict ventricular fibrillation with high accuracy</article-title>
          <source>J Appl Physiol</source>
          <date>
            <year>2002</year>
          </date>
          <fpage>541</fpage>
          <lpage>549</lpage>
          <volume>92</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Nearing</surname>
              <given-names>BD</given-names>
            </name>
            <name>
              <surname>Verrier</surname>
              <given-names>RL</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B38">
        <mixed-citation>38. Verrier RL,    Nearing BD, La Rovere MT, et al. Ambulatory electrocardiogram-based tracking    of T-wave alternans in postmyocardial infarction patients to assess risk of    cardiac arrest or arrhythmic death. J Cardiovasc Electrophysiol 2003;14:705-711.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Ambulatory electrocardiogram-based tracking of T-wave alternans in postmyocardial infarction patients to assess risk of cardiac arrest or arrhythmic death</article-title>
          <source>J Cardiovasc Electrophysiol</source>
          <date>
            <year>2003</year>
          </date>
          <fpage>705</fpage>
          <lpage>711</lpage>
          <volume>14</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Verrier</surname>
              <given-names>RL</given-names>
            </name>
            <name>
              <surname>Nearing</surname>
              <given-names>BD</given-names>
            </name>
            <name>
              <surname>La Rovere</surname>
              <given-names>MT</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B39">
        <mixed-citation>39. Shusterman    V, Goldberg A. Tracking repolarization dynamics in real-life data. J Electrocardiol    2004;37:180-186.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Tracking repolarization dynamics in real-life data</article-title>
          <source>J Electrocardiol</source>
          <date>
            <year>2004</year>
          </date>
          <fpage>180</fpage>
          <lpage>186</lpage>
          <volume>37</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Shusterman</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Goldberg</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B40">
        <mixed-citation>40. Shusterman    V, Goldberg A, London B. Upsurge in T-wave alternans and nonalternating repolarization    instability precedes spontaneous initiation of ventricular tachyarrhythmias    in humans. Circulation 2006;113:2880-2887.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Upsurge in T-wave alternans and nonalternating repolarization instability precedes spontaneous initiation of ventricular tachyarrhythmias in humans</article-title>
          <source>Circulation</source>
          <date>
            <year>2006</year>
          </date>
          <fpage>2880</fpage>
          <lpage>2887</lpage>
          <volume>113</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Shusterman</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Goldberg</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>London</surname>
              <given-names>B</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B41">
        <mixed-citation>41. Lampert R,    Soufer R, McPherson CA, et al. Implantable cardioverter-defibrillator shocks    increase T-wave alternans. J Cardiovasc Electrophysiol 2007;18:1-6.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Implantable cardioverter-defibrillator shocks increase T-wave alternans</article-title>
          <source>J Cardiovasc Electrophysiol</source>
          <date>
            <year>2007</year>
          </date>
          <fpage>1</fpage>
          <lpage>6</lpage>
          <volume>18</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Lampert</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Soufer</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>McPherson</surname>
              <given-names>CA</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B42">
        <mixed-citation>42. Verrier RL,    Nearing BD, Kwaku KF. Noninvasive sudden death risk stratification by ambulatory    ECG-based T-wave alternans analysis: Evidence and methodological guidelines.    Ann Noninv Electrocardiol 2005;10:110-120.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Noninvasive sudden death risk stratification by ambulatory ECG-based T-wave alternans analysis: Evidence and methodological guidelines</article-title>
          <source>Ann Noninv Electrocardiol</source>
          <date>
            <year>2005</year>
          </date>
          <fpage>110</fpage>
          <lpage>120</lpage>
          <volume>10</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Verrier</surname>
              <given-names>RL</given-names>
            </name>
            <name>
              <surname>Nearing</surname>
              <given-names>BD</given-names>
            </name>
            <name>
              <surname>Kwaku</surname>
              <given-names>KF</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B43">
        <mixed-citation>43. Kop WJ, Krantz    DS, Nearing BD, et al. Effects of acute mental stress and exercise on T-wave    alternans in patients with implantable cardioverter defibrillators and controls.    Circulation 2004;109:1864-1869.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Effects of acute mental stress and exercise on T-wave alternans in patients with implantable cardioverter defibrillators and controls</article-title>
          <source>Circulation</source>
          <date>
            <year>2004</year>
          </date>
          <fpage>1864</fpage>
          <lpage>1869</lpage>
          <volume>109</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Kop</surname>
              <given-names>WJ</given-names>
            </name>
            <name>
              <surname>Krantz</surname>
              <given-names>DS</given-names>
            </name>
            <name>
              <surname>Nearing</surname>
              <given-names>BD</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B44">
        <mixed-citation>44. Stein PK, Sanghavi    D, Domitrovich PP, et al. Amubulatory ECG-based T-wave alternans predicts sudden    cardiac death in high-risk post-MI patients with left ventricular dysfunction    in the EPHESUS study. J Cardiovasc Electrophysiol 2008 Jun 12 [Epub ahead    of print] doi: 10.1111/j.1540-8167.2008.01225.x.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Amubulatory ECG-based T-wave alternans predicts sudden cardiac death in high-risk post-MI patients with left ventricular dysfunction in the EPHESUS study</article-title>
          <source>J Cardiovasc Electrophysiol</source>
          <date>
            <year>2008</year>
            <month>06</month>
            <day>12</day>
          </date>
          <person-group person-group-type="author">
            <name>
              <surname>Stein</surname>
              <given-names>PK</given-names>
            </name>
            <name>
              <surname>Sanghavi</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Domitrovich</surname>
              <given-names>PP</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B45">
        <mixed-citation>45. Armoundas AA,    Albert CM, Cohen RJ, et al. Utility of implantable cardioverter defibrillators    electrograms to estimate repolarization alternans preceding a tachyarrhythmic    event. J Cardiovasc Electrophysiol 2004;15:594-597.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Utility of implantable cardioverter defibrillators electrograms to estimate repolarization alternans preceding a tachyarrhythmic event</article-title>
          <source>J Cardiovasc Electrophysiol</source>
          <date>
            <year>2004</year>
          </date>
          <fpage>594</fpage>
          <lpage>597</lpage>
          <volume>15</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Armoundas</surname>
              <given-names>AA</given-names>
            </name>
            <name>
              <surname>Albert</surname>
              <given-names>CM</given-names>
            </name>
            <name>
              <surname>Cohen</surname>
              <given-names>RJ</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B46">
        <mixed-citation>46. Oliveira MM,    Fiarresga A, Pelicano N, et al. Temporal variations in microvolt T-wave alternans    testing after acute myocardial infarction. Ann Noninv Electrocardiol 2007;12:98-103.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Temporal variations in microvolt T-wave alternans testing after acute myocardial infarction</article-title>
          <source>Ann Noninv Electrocardiol</source>
          <date>
            <year>2007</year>
          </date>
          <fpage>98</fpage>
          <lpage>103</lpage>
          <volume>12</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Oliveira</surname>
              <given-names>MM</given-names>
            </name>
            <name>
              <surname>Fiarresga</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Pelicano</surname>
              <given-names>N</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B47">
        <mixed-citation>47. Harada M, Shimizu    A, Murata M, et al. Relation between microvolt-level T-wave alternans and cardiac    sympathetic nervous system abnormality using iodine-123 metaiodobenzylguanidine    imaging in patients with idiopathic dilated cardiomyopathy. Am J Cardiol 2003;92:998-    1001.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Relation between microvolt-level T-wave alternans and cardiac sympathetic nervous system abnormality using iodine-123 metaiodobenzylguanidine imaging in patients with idiopathic dilated cardiomyopathy</article-title>
          <source>Am J Cardiol</source>
          <date>
            <year>2003</year>
          </date>
          <fpage>998</fpage>
          <lpage> 1001</lpage>
          <volume>92</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Harada</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Shimizu</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Murata</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B48">
        <mixed-citation>48. Lampert R,    Shusterman V, Burg MM, et al. Effects of psychologic stress on repolarization    and relationship to autonomic and hemodynamic factors. J Cardiovasc Electrophysiol    2005;16:372-377.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Effects of psychologic stress on repolarization and relationship to autonomic and hemodynamic factors</article-title>
          <source>J Cardiovasc Electrophysiol</source>
          <date>
            <year>2005</year>
          </date>
          <fpage>372</fpage>
          <lpage>377</lpage>
          <volume>16</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Lampert</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Shusterman</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Burg</surname>
              <given-names>MM</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B49">
        <mixed-citation>49. Lampert R,    Jain D, Burg MM, et al. Destabilizing effects of mental stress on ventricular    arrhythmias in patients with implantable cardioverter-defibrillators. Circulation    2000;101:158-164.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Destabilizing effects of mental stress on ventricular arrhythmias in patients with implantable cardioverter-defibrillators</article-title>
          <source>Circulation</source>
          <date>
            <year>2000</year>
          </date>
          <fpage>158</fpage>
          <lpage>164</lpage>
          <volume>101</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Lampert</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Jain</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Burg</surname>
              <given-names>MM</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B50">
        <mixed-citation>50. Ferrero P,    Castagno D, Massa R, et al. Spinal cord stimulation affects T-wave alternans    in patients with ischaemic cardiomyopathy: A pilot study. Europace 2008;10:506-508.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Spinal cord stimulation affects T-wave alternans in patients with ischaemic cardiomyopathy: A pilot study</article-title>
          <source>Europace</source>
          <date>
            <year>2008</year>
          </date>
          <fpage>506</fpage>
          <lpage>508</lpage>
          <volume>10</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Ferrero</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Castagno</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Massa</surname>
              <given-names>R</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B51">
        <mixed-citation>51. Mitchell LB,    Pineda EA, Titus JL, et al. Sudden death in patients with implantable cardioverter    defibrillators - the importance of post-shock electromechanical dissociation.    J Am Coll Cardiol 2002;39:1323-1328.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Sudden death in patients with implantable cardioverter defibrillators - the importance of post-shock electromechanical dissociation</article-title>
          <source>J Am Coll Cardiol</source>
          <date>
            <year>2002</year>
          </date>
          <fpage>1323</fpage>
          <lpage>1328</lpage>
          <volume>39</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Mitchell</surname>
              <given-names>LB</given-names>
            </name>
            <name>
              <surname>Pineda</surname>
              <given-names>EA</given-names>
            </name>
            <name>
              <surname>Titus</surname>
              <given-names>JL</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
    </ref-list>
  </back>
  <sub-article article-type="translation" id="TRen" xml:lang="en">
    <front-stub>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Original Articles</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title xml:lang="en">T-wave alternans: clinical performance, limitations and analysis methodologies</article-title>
      </title-group>
      <abstract xml:lang="en">
        <p>Accurate recognition of individuals at higher immediate risk of sudden cardiac death (SCD) is still an open question. The fortuitous nature of acute cardiovascular events just does not seem to fit the well-known model of ventricular tachycardia/fibrillation induction in a static arrhythmogenic substrate by a synchronous trigger. On the mechanism of SCD, a dynamical electrical instability would better explain the rarity of the simultaneous association of a correct trigger and an appropriate cardiac substrate. Several studies have been conducted trying to measure this cardiac electrical instability (or any valid surrogate) in an ECG beat stream. Among the current possible candidates we can number QT prolongation, QT dispersion, late potentials, T-wave alternans (TWA), and heart rate turbulence. This article reviews the particular role of TWA in the current cardiac risk stratification scenario. TWA findings are still heterogeneous, ranging from very good to nearly null prognostic performance depending on the clinical population observed and clinical protocol in use. To fill the current gaps in the TWA base of knowledge, practitioners, and researchers should better explore the technical features of the several technologies available for TWA evaluation and pay greater attention to the fact that TWA values are responsive to several factors other than medications. Information about the cellular and subcellular mechanisms of TWA is outside the scope of this article, but the reader is referred to some of the good papers available on this topic whenever this extra information could help the understanding of the concepts and facts covered herein.</p>
      </abstract>
      <kwd-group xml:lang="en">
        <kwd>Arrhythmias, cardiac</kwd>
        <kwd>death, sudden</kwd>
        <kwd>defibrillators, implantable</kwd>
        <kwd>United States</kwd>
        <kwd>Estados Unidos</kwd>
      </kwd-group>
    </front-stub>
    <body>
      <p>
        <fn id="top-body2">
          <label>
            <bold>T-wave alternans: clinical performance, limitations and analysis methodologies</bold>
          </label>
          <p>
            <bold>Euler V. Garcia<sup>I, II</sup>; Carlos Alberto Pastore<sup>I</sup>; Nelson Samesima<sup>I</sup>; Hor&#225;cio G. Pereira Filho<sup>I</sup></bold>
          </p>
        </fn>
      </p>
      <p><sup>I</sup>Servi&#231;o de Eletrocardiologia - Instituto do Cora&#231;&#227;o (InCor) do Hospital das Cl&#237;nicas - Faculdade de Medicina da Universidade de S&#227;o Paulo, S&#227;o Paulo, SP</p>
      <p><sup>II</sup>Universidade de Bras&#237;lia - Campus Gama, Bras&#237;lia, DF - Brazil</p>
      <p>Mailing address</p>
      <p>
        <bold>ABSTRACT</bold>
      </p>
      <p>Accurate recognition of individuals at higher immediate risk of sudden cardiac death (SCD) is still an open question. The fortuitous nature of acute cardiovascular events just does not seem to fit the well-known model of ventricular tachycardia/fibrillation induction in a static arrhythmogenic substrate by a synchronous trigger. On the mechanism of SCD, a dynamical electrical instability would better explain the rarity of the simultaneous association of a correct trigger and an appropriate cardiac substrate. Several studies have been conducted trying to measure this cardiac electrical instability (or any valid surrogate) in an ECG beat stream. Among the current possible candidates we can number QT prolongation, QT dispersion, late potentials, T-wave alternans (TWA), and heart rate turbulence. This article reviews the particular role of TWA in the current cardiac risk stratification scenario. TWA findings are still heterogeneous, ranging from very good to nearly null prognostic performance depending on the clinical population observed and clinical protocol in use. To fill the current gaps in the TWA base of knowledge, practitioners, and researchers should better explore the technical features of the several technologies available for TWA evaluation and pay greater attention to the fact that TWA values are responsive to several factors other than medications. Information about the cellular and subcellular mechanisms of TWA is outside the scope of this article, but the reader is referred to some of the good papers available on this topic whenever this extra information could help the understanding of the concepts and facts covered herein.</p>
      <p><bold>Keywords:</bold> Arrhythmias, cardiac/prevention &amp; control; death, sudden/prevention &amp; control; defibrillators, implantable; United States/epidemiology.</p>
      <p>In general, most cases of sudden cardiac death (SCD) are related to coronary artery disease and dilated and hypertrophic non-ischemic cardiomyopathy<sup>1</sup>. Equally important are the cases of SCD reported in apparently healthy individuals. Between 1994 and 2003, in the United Kingdom, the autopsies of 453 individuals aged 15 to 81 years who died due to SDC were performed. Among this set, 269 (59.3%) of the hearts were macroscopically and microscopically normal<sup>2</sup>.</p>
      <p>The precise identification of individuals at higher immediate risk of SCD remains an open question. Many factors (acquired or congenital; structural, functional or genetic ones) are related to an increase in the risk of SCD; however, when considered alone, they cannot identify individuals at maximum risk. Vigorous physical activity (6 METS or more) can potentially increase the risk of acute cardiovascular events; however, the rarity of exercise-related events gives a clear indication that an additional specific cardiac substrate is necessary, according to the joint statement of the American Heart Association and the American College of Sports Medicine<sup>3</sup>.</p>
      <p>In other words, the apparently random nature of an acute cardiovascular event well exemplifies that the typical pathophysiological mechanism of the CSD does not seem to be a trigger in synchronism with a static arrhythmogenic substrate, so that a ventricular tachycardia (VT) or fibrillation can start. On the contrary, the electrical instability would be dynamic, which would explain the low probability of a specific trigger associated with an appropriate cardiac substrate<sup>4</sup>.</p>
      <p>Hence, how can the dynamics of electrical instability be measured? During the last decades, several studies have been conducted trying to measure this cardiac electrical instability (or any valid surrogate) in an ECG beat stream. These studies, in general, used two main approaches: 1) to quantify how the measured variable would be associated to the tendency toward future arrhythmias and 2) to evaluate how fast the myocardium recovers after a small electrical arrhythmia (for instance, an extra-systole) and the consequences of this fact on a future prognosis. Such approaches are similar at first glance, but this conclusion is not real. Based on the usual vocabulary of clinical arrhythmias, in which primary and secondary prevention mean, respectively, prevention before and after a cardiovascular event, one could call the first "instability primary to arrhythmia" and the second "instability secondary to arrhythmia". Among the clinical measurements of primary instability, we can mention the QT prolongation, QT dispersion, Late Potentials and T-wave alternans (TWA). The Heart Rate Turbulence, on the other hand, would be a measurement of the secondary instability group.</p>
      <p>This review will emphasize the role of TWA in the current scenario of cardiac risk stratification. Due to the abundant literature on the subject, this review will be divided in four sections. After defining and reporting a summarized history of TWA, the second section will report its prognostic performance in different populations. As the TWA is an examination that depends essentially on technology, the third section will make considerations on a crucial aspect for the clinical performance of TWA: the available technological approaches and its consequent options of analysis and limitations. The fourth section will explore other factors that can modulate the values and influence the TWA assessments.</p>
      <p>
        <bold>Definition of TWA and summarized history</bold>
      </p>
      <p>The so-called TWA is an oscillation in the regular amplitude in the ST-T portion of the ECG tracing that occurs with half of the heart rate. In other words, the alterations in the ST-T amplitude repeat at every two beats, so that a pattern of amplitude with even beats and another one with odd beats can be created. For didactic purposes, we can summarize the chronological history of TWA in three distinct phases: the transition of the focus of research, from macroscopic TWA to microscopic TWA; the impact of TWA in microvolts in protocols of risk stratification and health policies; and the establishment of a solid experimental basis for the current clinical discoveries on TWA.</p>
      <p>The macroscopic TWA (visual) has been reported since the beginning of electrocardiography<sup>5</sup>, always associated with a poor prognosis and considered a rare finding, up to the first publication on the invisible (microscopic) TWA in 1980<sup>6</sup>. Since then, several groups have studied TWA and each group has done so differently. A direct consequence of this fact was the review published in 2005, listing more than 10 different technologies for its assessment<sup>7</sup>; however, its results were even more restricted to specific segments of the cardiologic research community. The next step - when the TWA captured the attention of clinical cardiologists, in addition to cardiology researchers - took place in the beginning of the XXI century, with the publication of evidence that the TWA would be able to reduce the mean number of implantable cardioverter defibrillators (ICD) necessary to, in fact, save a life<sup>8</sup>.</p>
      <p>At that time, the alternation in the duration of the action potential duration (APD-alternans) had also been intensely studied throughout the years. In 2002, evidence was obtained that the APD-alternans was the first link in a dictated progression of oscillation patterns of amplitude that were increasingly complex, up to a ventricular fibrillation (VF) during ischemia<sup>9</sup> and also that atrial APD-alternans had been recorded, consistently, before the transition from one atrial flutter to an atrial fibrillation<sup>10</sup>. Additionally, it was discovered that the TWA and APD-alternans were associated to each other in experimental studies<sup>11</sup>, but until then, there had been no evidence that this association persisted, even in clinical contexts.</p>
      <p>The third phase of the TWA research started with the solution of this clinical puzzle. First, it was demonstrated that patients with cardiomyopathy and inducible VT or a positive TWA test presented a more heterogeneous repolarization (in both the epicardium and the endocardium) than in those individuals without inducible VT or with a negative TWA test<sup>12</sup>. Later, the TWA was consistently associated to the endocardial and epicardial APD-alternans, so that a minimum number of sites with APD-alternans was always necessary for the TWA to be successfully measured on the body surface; however, the isolated APD-alternans were not always associated to TWA on the body surface<sup>13</sup>.</p>
      <p>Currently, the TWA presents as a valid clinical surrogate of the APD-alternans, the latter being an important marker of cardiac electrical instability. The interested reader can refer to several publications on the mechanisms of the genesis of APD-alternans and its association with the arrhythmogenic cardiac substrate<sup>4,14-17</sup>. These experimental fundaments aggregate value to the stratification performance through TWA in different clinical populations, which is reviewed in the following section.</p>
      <p>
        <bold>Twa and cardiac risk stratification</bold>
      </p>
      <p>
        <bold>Coronary or ischemic heart diseases</bold>
      </p>
      <p>The second Multicenter Automatic Defibrillator Implantation Trial - MADIT-2 -brought convincing evidence on a decrease in mortality with the use of the ICD. Its findings showed a global decrease of 31% in the risk of mortality in post-infarction patients with left ventricular ejection fraction (LVEF) <underline>&lt;</underline> 30%, regardless of the fact whether the patients presented more advanced stages of the disease, thus defined through the NYHA functional class and level of urea nitrogen in the blood (decrease of 28-35%, regardless of the basal mortality risk in the subgroups)<sup>18</sup>. In 2003, the American Centers for Medicare and Medicaid Services - CMS - decided to cover the costs of the prophylactic treatment with ICD for patients of the MADIT-2 type and QRS duration &gt; 120 ms. In 2005, the CMS decided to include all patients of the MADIT-2 type<sup>19</sup>, but the cost-benefit was still a matter of concern and there was a clear need for a better risk stratification<sup>20</sup>.</p>
      <p>The evaluation of the TWA in 177 patients of the MADIT-2 type resulted in a better risk stratification performance than that of the QRS duration. Patients with a narrow QRS (QRS &lt; 120 ms) were not free from the risk of sustained ventricular arrhythmias (SVT) during a two-year follow-up (mortality rate = 14%, similar to that of MADIT-2). On the other hand, the group of patients with normal TWA recorded only 2 deaths within the same period (actuarial mortality rate of 3.8%), whereas the set with abnormal TWA presented a hazard ratio (HR) of 4.8 (P = 0,012) for mortality due to all causes, adjusted for the duration of QRS. In MADIT-2, 18 ICD were necessary to save a life; however, when using the strategy of TWA examinations, only 7 ICD were necessary to save one life<sup>8</sup>.</p>
      <p>A prospective cohort study encompassing 768 ischemic patients with LVEF <underline>&lt;</underline> 35% and with no previous sustained VT (51% received ICD) gave strong evidence that the benefits of the ICD differed according to the level of the TWA, decreasing the mortality due to all causes (HR = 0.45, 95% CI = [0.27, 0.76], P = 0.003) in patients with non-negative TWA (positive or undetermined), but without decreasing the mortality in the group with negative TWA (HR = 0.85, 95% CI = [0.33, 2.20], P = 0.73). Moreover, it was also demonstrated that such findings were mostly due to the decrease in the arrhythmic mortality. Regarding the effectiveness of the ICD therapy, 9 ICD were necessary to save one life during a two-year period in patients with non-negative TWA; however, 76 ICD were necessary to save one life, during the same period of time, in the group with negative TWA<sup>21</sup>.</p>
      <p>
        <bold>After acute myocardial infarction</bold>
      </p>
      <p>Regarding the capacity to predict severe arrhythmic events, in the context of preserved cardiac function after acute myocardial infarction (AMI), a Japanese prospective study (n = 1,041; 79% men) observed that the TWA showed a prognostic performance that was similar to studies in populations post-AMI with decreased LVEF. The TWA tests were carried out at least 14 days post-AMI, with 169 (17%) positive, 747 (74%) negative and 87 (9%) undetermined tests, with a general sensitivity and negative predictive value of 81% and 99.6%, respectively; the multivariate analysis showed HR = 19.7 - 95% CI= (5.5-70.4), P &lt; 0.0001 for arrhythmic events<sup>22</sup>.</p>
      <p>The REFINE (Risk Estimation Following Infarction, Noninvasive Evaluation) study evaluated the prognostic performance of the autonomic tonus and/or cardiac electrical substrate evaluation in the identification of patients at higher cardiac risk soon after the AMI. In brief, no isolated parameter (TWA, heart rate turbulence, baroreflex sensitivity), in an assessment carried out 2 to 4 weeks (acute phase) after the AMI successfully predicted outcomes. The best diagnostic precision in the non-acute phase (10 to 14 weeks) after the AMI was obtained by combining the abnormal TWA and the HR turbulence, plus LVEF &lt; 50%. This composite indicator correctly identified two thirds of all patients that suffered a heart attack, with a sensitivity of 55%, specificity of 86% and a negative predictive value of 90%. It is noteworthy the fact that the TWA measured during exercise-induced stress or in a Holter registry presented similar performance, although it had been assessed with a different technology in each case. In a multivariate analysis adjusted for age, sex, previous AMI and diabetes, the indicator comprising Holter assessment and TWA resulted in HR = 6.22 - 95% CI = (2.88 - 13.47), P &lt; 0.001, and the combination with exercise TWA resulted in HR = 5.08 - 95% CI = (2.17 - 11.89), P &lt; 0.001<sup>23</sup>.</p>
      <p>Differently from the findings of the REFINE study, another study on the TWA assessment during the period of 7 to 30 days after the AMI (n = 119) resulted in 17 (14%) undetermined, 50 (42%) positive and 52 (44%) negative tests. During a follow-up period of 3 to 23 months, the TWA presented the best prognostic value among the indicators (TWA, late potentials, ejection fraction): 14 of the 15 patients with arrhythmic events presented positive TWA, with the best sensitivity and negative predictive value among all analyzed parameters (93% and 98%, respectively; relative hazard of 16.8, P = 0.006)<sup>24</sup>.</p>
      <p>The TWA showed to be very efficient in risk stratification in post-AMI patients with LVEF <underline>&lt;</underline> 30%, regardless of the stage of the disease. Therefore, as a non-invasive method, it can be an important tool in the assessment of patients with ischemic disease.</p>
      <p>
        <bold>Apparently healthy individuals and general population</bold>
      </p>
      <p>
        <bold>Adults</bold>
      </p>
      <p>The prevalence of TWA was assessed at rest and during physical exertion in apparently healthy group (none received permanent medication) of 48 individuals (aged 21-53 years, 29 men). Functional and structural heart diseases were excluded through the clinical history and the ECG assessment at rest and during exertion, as well as a Doppler echocardiography. Transient TWA episodes were observed in 5 individuals (10.4%). Sustained TWA was observed in 2 individuals (4.2%); however, only one (2.1%) met all criteria for positivity and none of the 48 individuals developed morbidity due to arrhythmia during the follow-up period of 12-40-months<sup>25</sup>. A larger study (110 healthy individuals, aged 20-75 years, 76 men) was published in the same year and 5 individuals (5%) presented a positive, 98 (89%) presented a negative and 7 (6%) presented an undetermined TWA test. Once again, no morbidity or mortality due to arrhythmia was reported during the follow-up of 32 &#177; 15 months<sup>26</sup>.</p>
      <p>
        <bold>Younger than 18</bold>
      </p>
      <p>The TWA was assessed in 100 normal volunteers (8-17 years, with no history of heart disease, normal clinical examination and resting ECG). The excess noise hampered the adequate recording of data during exercise of 16 volunteers and the data at rest of other 24 volunteers; however, all other 76 volunteers had a negative TWA at rest. Nine volunteers (11% of the valid tests) presented sustained alternans, all of whom presented higher initial heart rates than the usual adult criteria: they varied from 120 to 158 bpm, whereas the usual threshold of initial HR is <underline>&lt;</underline> 110 bpm<sup>27</sup>.</p>
      <p>
        <bold>General population</bold>
      </p>
      <p>A sub-study of the FINCAVAS (Finnish Cardiovascular Study) described the TWA assessment in a cohort of 1,037 patients (61.4% men, 58 &#177; 13 years), extracted from a general population, all referred to exercise stress test. The clinical indications for the exercise test included the diagnosis of coronary heart disease (46%), vulnerability to exercise-induced arrhythmia (18%), assessment of cardiac performance capacity (19%), treatment adequacy for coronary heart disease (24%), patient profile assessment before invasive surgery (13%) and evaluation after acute myocardial infarction (10%). The exercise-induced TWA, with a cutoff of 47 <italic>&#181;</italic>V or 65 <italic>&#181;</italic>V, was strongly predictive of SCD (RR = 2.9, P = 0.02 and RR = 7.4, P &lt; 0.001, respectively), as well as of cardiovascular death (RR = 2.6, P = 0.01 and RR = 6.0, P &lt; 0.001), yielding excellent negative predictive values, both close to 98%<sup>28</sup>.</p>
      <p>
        <bold>Athletes</bold>
      </p>
      <p>Amateur soccer players with and without mitral valve prolapse and sedentary individuals, paired by age (three groups of 20 individuals) presented no positive TWA tests when submitted to normal protocols of exercise-induced stress<sup>29</sup>. TWA assessment and electrophysiology studies (EPS) were also carried out in professional athletes from several sports, both healthy ones (n = 48) and those presenting important arrhythmias, although without arrhythmogenic pathologies (n = 52). None of the healthy athletes presented a positive test or any event during the mean follow-up of 36 months. On the other hand, 7 of the 52 (13.5%) of the athletes with arrhythmia had a positive TWA test, 5 of whom also presented a positive EPS result for VT and one a positive result for severe supraventricular tachycardia (the other refused to undergo the EPS). In the group of arrhythmic athletes, all 42 negative TWA tests were also accompanied by negative EPS results, except for one, who was specifically being treated with amiodarone. However, this individual with negative TWA/positive EPS did not present any event during the 25.3-month follow-up<sup>30</sup>.</p>
      <p>A recent study in athletes with ventricular arrhythmia (n = 85, 61 men) emphasized the good correlation between the TWA and the EPS results in this population. Similar numbers have been described for positive TWA tests (15 in 85, 18%) with a lower frequency of negative TWA tests (57/85, 68%) and more undetermined tests (13/85, 14%). All athletes with a positive TWA test had a positive EPS result and all athletes with a negative TWA test had a negative EPS result. No correlation was observed between the undetermined TWA and EPS results. Regarding the occurrence of events, athletes with negative TWA tests did not present any event during a mean follow-up of 30 months; however, 5 individuals with positive TWA, as well as 2 individuals with undetermined TWA tests reported events that occurred during this period<sup>31</sup>.</p>
      <p>TWA can become a good tool for risk stratification in normal individuals, but further studies are necessary, with samples of adequate sizes, to be able to count on reliable data concerning these populations.</p>
      <p>
        <bold>Twa analytical methodologies</bold>
      </p>
      <p>TWA is a type of examination that depends essentially on the used technology, as the typical oscillations of its amplitude (with a magnitude of a few 1/50 mm at a normal gain of 10 mm/mV) are beyond the physician's visual assessment. As mentioned before, there are several distinct methodologies to assess TWA. Thus, the choice of a methodology will have a direct impact on the measured values and the clinical limitations of the TWA, even if the different TWA algorithms present a similar clinical performance<sup>23,32</sup>. This section aims at summarizing the basic concepts, in addition to differentiating the characteristics and clinical limitations of the most relevant methodologies developed for the analysis of TWA. Therefore, we considered relevant only the two TWA analysis algorithms that are available commercially (spectral method and Modified Moving Average) and the most similar research methodologies (Complex Demodulation and Intrabeat average).</p>
      <p>How is TWA measured? Recalling the definition of TWA, the basic concept is the frequency. When present, the TWA occurs always in the middle of the heart rate, or, in other words, at a frequency of 0.5 cycle per beat (cpb). Whenever we think about the automatic detection of TWA, this is the only available information, theoretically, as no one knows beforehand if it will be present or not, which part of the ST-T complex will show alternans or even what magnitude will the recorded alternans present. It is quite similar to turning on a stereo radio station in the car: we know the radio frequency that interests us, but we cannot predict whether there will be any relevant information in it, or just noise. Based on this distinctive characteristic of the TWA - fixed frequency - it seemed logical (or natural) the fact that the first forms of TWA analysis had been based on the tracking of this 0.5 cpb frequency. This approach is currently found in the spectral method (SM) and the complex demodulation (CM) method.</p>
      <p>
        <bold>Spectral method (SM)</bold>
      </p>
      <p>The SM measures T-wave fluctuations by computing differences point by point between 128 equidistant sites in the ST-T in a series of 128 consecutive aligned beats (disregarding the ectopic beats and those with noise)<sup>33</sup>. In other words, there are 128 tachograms similar to those used in the analysis of the HR variability. Subsequently, 128 frequency spectra are registered (thus the name of the method - SM) and their mean is calculated. The TWA value is then assessed at the frequency of 0.5 cpb (<xref ref-type="fig" rid="en_00811f01-body2">Figure 1</xref>). The adaptation of this technique for human patients was first published in 1994<sup>34</sup>. Since then, it has been the most often used method of TWA analysis, presenting the largest range of use.</p>
      <p content-type="asset">
        <fig id="en_00811f01-body2">
          <graphic xlink:href="1678-4170-abc-96-03-0e53-00018-gf01-en.jpg"/></fig>
      </p>
      <p>
        <bold>Complex demodulation (CD)</bold>
      </p>
      <p>The CD method was presented at a later date than the SM<sup>36</sup>, as an alternative algorithm. Basically, this method evaluates only the energy at the area close to the alternans frequency of 0.5 cpb, instead of calculating the fluctuations along a broad frequency band, as the SM does.</p>
      <p>As the field of research of TWA matured, a new family of algorithms appeared, all based on the comparison of beat patterns. This approach is currently found in the Modified Moving Average and the Intrabeat Average methods.</p>
      <p>
        <bold>Modified moving average (MMA)</bold>
      </p>
      <p>The MMA creates, resourcefully, two patterns (models) of beats based on any sequence of valid beats (with one pattern being associated only to the even beats and another to the odd beats). To elucidate each of the beat patterns, the iterative algorithm is as follows: the differences in amplitude between the current pattern (of even or odd beats) and the next valid beat (even or odd) are measured along several equidistant sites in the ST-T complex. Each one of these differences is divided in X equal parts (where X can be 8, 16, 32 or 64) and the contribution of the current valid beat to the update of the pattern-beat is then limited to 1/X (called updating factor or limiting fraction) of the differences between model and beat (<xref ref-type="fig" rid="f2-body2">Figure 2</xref>). Finally, the TWA values are made available every 15 seconds, as the difference between the two representative patterns (and continuously updated) of the even and odd beats<sup>37</sup>.</p>
      <fig id="f2-body2">
        <graphic xlink:href="1678-4170-abc-96-03-0e53-00018-gf02-en.jpg"/></fig>
      <p>
        <bold>Intrabeat average (IBA)</bold>
      </p>
      <p>The concept and the characteristics of the intrabeat average (IBA) are very similar to those presented in the MMA method. Its distinctive feature is the separation of the ST-T complex into three time intervals (T-initial to T-peak - which includes the ST segment; T-peak to T-final; T-initial to T-final) and the computation of distinct values of TWA for each one of them<sup>39-41</sup>.</p>
      <p>
        <bold>Factors that modulate TWA</bold>
      </p>
      <p>
        <bold>Physiological and pathophysiological alterations</bold>
      </p>
      <p>Initial findings obtained in Holter studies affirmed that the magnitude of the TWA responded to circadian fluctuations and physiological alterations<sup>40,42,43</sup>. Multivariate analyses of 24-hour ambulatory ECG, recorded in patients from the database of the ATRAMI (Autonomic Tone and Reflexes After Myocardial Infarction) trial, showed that the TWA levels &gt; 75<sup>th</sup> percentile at 8 AM or at the maximum heart rate (around 47 <italic>&#181;</italic>V) were related to higher chances of having a heart attack (documented VF) or arrhythmic death during the follow-up period (OR ranged from 4.2 to 7.9, depending on the lead [electrode] and the time period)<sup>38</sup>. Later, Stein et al<sup>44</sup> noticed that, on average, the higher levels of TWA accompanied the circadian cycle of increase in the risk of sudden death in patients with heart failure. Moreover, it was observed that the TWA levels &gt; 47 <italic>&#181;</italic>V were associated with an increased risk of SCD.</p>
      <p>On pathological processes that affect the magnitude of the TWA, Shusterman et al<sup>40</sup> demonstrated an increase in the TWA magnitude preceding the spontaneous start of ventricular tachyarrhythmias (VTA). Holter records (n=59) with spontaneous VTA were selected from the database of the ESVEM (Electrophysiologic Study Versus Electrocardiographic Monitoring) clinical trial. Its results showed that the TWA magnitude increased continuously from the baseline to a peak of 25%, 10 minutes before the event. Researchers from the TOVA (Triggers of Ventricular Arrhythmias) study also verified the existence of significant TWA magnitude before the start of the arrhythmia, using electrograms<sup>45</sup>. Post-infarction temporal alterations in TWA during the first 6 months after the event have also been recorded, probably after ventricular remodeling post-acute myocardial infarction<sup>46</sup>. Eventually, the TWA at pathological levels was associated to the cardiac sympathetic denervation and accelerated sympathetic nervous activity in patients with dilated idiopathic cardiomyopathy during Iodine 123-labeled metaiodobenzylguanidine (123I-MIBG) assessment and echocardiogram<sup>47</sup>.</p>
      <p>Other studies investigated the effects of acute mental stress (by recalling memories that triggered anger or by doing mental arithmetics) on the TWA. Kop et al<sup>43</sup> concluded that this increases the TWA amplitude in patients with ICD, with documented coronary artery disease (n = 23) at lower heart rates than those in the exercise protocols currently used in the assessment of TWA<sup>43</sup>. Lampert et al<sup>48</sup> not only recorded an increase in TWA due to mental stress in patients with ICD (n = 33), but also discovered that the TWA alterations were well correlated with alterations in HR, systolic blood pressure and catecholamine levels<sup>48</sup>, in line with previous evidence that the mental stress alters not only the cycle length, but also the VT cessation in patients with ICD without ischemia<sup>49</sup>.</p>
      <p>Finally, some external influences can also affect the TWA. The spinal column stimulation (SCS) is currently used in patients with untreatable angina and it is being considered that this stimulation has an anti-arrhythmic effect on the arrhythmogenic substrate. The study of the TWA patterns to assess alterations in the arrhythmic substrate indicates that patients that originally presented high-amplitude positive TWA tests when the stimulator was off, experienced a decrease in the TWA values (although still presenting a positive TWA test) 2 hours after the SCS. Twenty-four hours after the SCS, all patients became TWA-negative. In this sample, all patients were being treated with beta-blockers and no alterations in the basal HR or atrioventricular conduction were observed in consecutive TWA tests. These findings suggest an effect of time-dependent remodeling on the arrhythmogenic substrate (evaluated by TWA), independent from the sympathetic removal<sup>50</sup>.</p>
      <p>Another external influence - ICD shocks during normal defibrillation tests (n = 65) - acutely increased the TWA magnitude, mediated in part by sympathetic stimulation<sup>43</sup>. Moreover, further studies are necessary to demonstrate whether this increase in TWA can be associated to the most common mechanism of sudden death in patients with ICD<sup>51</sup>, i.e., the post-shock electromechanical dissociation that follows a treated VT/VF. On this subject, a key aspect to be considered is that problems in the calcium cell cycle - previously associated with the mechanical ventricular dysfunction - are strongly related to APD-alternans<sup>4,14,15,17</sup>.</p>
      <p>
        <bold>Final considerations</bold>
      </p>
      <p>The prognostic role of TWA in the clinical risk stratification is becoming increasingly clearer, but still comprises a few controversies. On the one hand, the currently available literature presents strong evidence of a good prognostic performance (notably, its negative predictive value) in specific clinical populations, such as ischemic heart disease, after AMI, non-ischemic cardiomyopathy. The TWA would also be equal to, or would have a better prognostic performance than EPS in other populations (for instance, athletes with arrhythmia). On the other hand, the clinical value of the TWA assessment has yet to be further investigated regarding many of its aspects, particularly: other clinical populations of relevance (for instance, Chagas' disease) must be studied; other study protocols (for instance, comparisons between TWA in Holter and exercise- or pharmacological stress-induced TWA) must be included; the technicalities of each methodology for TWA measurement must be considered correctly in the clinical protocols to be outlined.</p>
      <p>The next steps in the creation of new protocols and uses, in the deeper exploration of the clinical possibilities of TWA or the "filling in the current gaps" in the TWA knowledge basis follow a direction: physicians and researchers must better explore the technological characteristics of the several available technologies to assess the TWA - each one with its own strong and weak points - aware of the fact that the obtained TWA values respond to several other factors rather than medications.</p>
      <p>
        <bold>Potential Conflict of Interest</bold>
      </p>
      <p>No potential conflict of interest relevant to this article was reported.</p>
      <p>
        <bold>Sources of Funding</bold>
      </p>
      <p>There were no external funding sources for this study.</p>
      <p>
        <bold>Study Association</bold>
      </p>
      <p>This study is not associated with any post-graduation program.</p>
      <p>
        <bold>References</bold>
      </p>
    </body>
  </sub-article>
  <sub-article article-type="translation" id="TRes" xml:lang="es">
    <front-stub>
      <article-categories/>
      <title-group>
        <article-title xml:lang="es">T-wave alternans: desempe&#241;o cl&#237;nico, limitaciones, metodolog&#237;as de an&#225;lisis</article-title>
      </title-group>
      <abstract xml:lang="es">
        <p>Reconocer con precisi&#243;n individuos con mayor riesgo inmediato de muerte s&#250;bita card&#237;aca (MSC) aun es una cuesti&#243;n en abierto. La naturaleza fortuita de los eventos cardiovasculares agudos no parece adecuarse al conocido modelo de inducci&#243;n de taquicardia/fibrilaci&#243;n ventricular por un gatillo en sincron&#237;a con un substrato arritmog&#233;nico est&#225;tico. En cuanto al mecanismo de la MSC, una inestabilidad el&#233;ctrica din&#225;mica explicar&#237;a mejor la rareza de la asociaci&#243;n simult&#225;nea de un gatillo correcto a un substrato card&#237;aco apropiado. Diversos estudios trataron de medir esa inestabilidad el&#233;ctrica card&#237;aca (o un equivalente v&#225;lido) en una secuencia de latidos card&#237;acos en el ECG. Entre los mecanismos posibles podemos citar la prolongaci&#243;n del QT, dispersi&#243;n del QT, potenciales tard&#237;os, alternancia de onda T o T-wave alternans (TWA), y turbulencia de la frecuencia card&#237;aca. Este art&#237;culo se atiene en particular al papel de la TWA en el panorama actual de la estratificaci&#243;n de riesgo card&#237;aco. Los hallazgos sobre TWA aun son heterog&#233;neos, variando de un desempe&#241;o pron&#243;stico muy bueno hasta uno casi nulo, dependiendo de la poblaci&#243;n cl&#237;nica observada y protocolo cl&#237;nico usado. Para llenar las actuales lagunas en el conocimiento sobre TWA, profesionales m&#233;dicos e investigadores deben explotar mejor las caracter&#237;sticas t&#233;cnicas de las diversas tecnolog&#237;as disponibles para la evaluaci&#243;n de TWA y estar atento al hecho de que los valores de TWA responden a otros diversos factores, adem&#225;s de medicamentos. Informaciones sobre mecanismos celulares y subcelulares de la TWA est&#225;n fuera del objetivo de este art&#237;culo, pero son referenciados algunos de los principales trabajos sobre este t&#243;pico, con el prop&#243;sito de auxiliar en la comprensi&#243;n de los conceptos y hechos cubiertos en este art&#237;culo.</p>
      </abstract>
      <kwd-group xml:lang="es">
        <kwd>Arritmias card&#237;acas</kwd>
        <kwd>muerte s&#250;bita</kwd>
        <kwd>desfibriladores implantables</kwd>
      </kwd-group>
    </front-stub>
    <body>
      <p>
        <bold>ACTUALIZACI&#211;N CL&#205;NICA</bold>
      </p>
      <p>
        <fn id="enda-body3">
          <label>
            <bold>T-wave alternans: desempe&#241;o cl&#237;nico, limitaciones, metodolog&#237;as de an&#225;lisis </bold>
          </label>
          <p>
            <bold>Euler V. Garc&#237;a<sup>I,II</sup>; Carlos Alberto Pastore<sup>I</sup>; Nelson Samesima<sup>I</sup>; Horacio G. Pereira Filho<sup>I</sup></bold>
          </p>
        </fn>
      </p>
      <p><sup>I</sup>Servigo de Eletrocardiologia - Instituto do Cora&#231;&#227;o (InCor) do Hospital das Cl&#237;nicas - Faculdade de Medicina da Universidade de S&#227;o Paulo, S&#227;o Paulo, SP</p>
      <p><sup>II</sup>Universidade de Brasilia - Campus Gama, Brasilia, DF - Brasil </p>
      <p>Correspondencia</p>
      <p>
        <bold>RESUMEN </bold>
      </p>
      <p>Reconocer con precisi&#243;n individuos con mayor riesgo inmediato de muerte s&#250;bita card&#237;aca (MSC) aun es una cuesti&#243;n en abierto. La naturaleza fortuita de los eventos cardiovasculares agudos no parece adecuarse al conocido modelo de inducci&#243;n de taquicardia/fibrilaci&#243;n ventricular por un gatillo en sincron&#237;a con un substrato arritmog&#233;nico est&#225;tico. En cuanto al mecanismo de la MSC, una inestabilidad el&#233;ctrica din&#225;mica explicar&#237;a mejor la rareza de la asociaci&#243;n simult&#225;nea de un gatillo correcto a un substrato card&#237;aco apropiado. Diversos estudios trataron de medir esa inestabilidad el&#233;ctrica card&#237;aca (o un equivalente v&#225;lido) en una secuencia de latidos card&#237;acos en el ECG. Entre los mecanismos posibles podemos citar la prolongaci&#243;n del QT, dispersi&#243;n del QT, potenciales tard&#237;os, alternancia de onda T o T-wave alternans (TWA), y turbulencia de la frecuencia card&#237;aca. Este art&#237;culo se atiene en particular al papel de la TWA en el panorama actual de la estratificaci&#243;n de riesgo card&#237;aco. Los hallazgos sobre TWA aun son heterog&#233;neos, variando de un desempe&#241;o pron&#243;stico muy bueno hasta uno casi nulo, dependiendo de la poblaci&#243;n cl&#237;nica observada y protocolo cl&#237;nico usado. Para llenar las actuales lagunas en el conocimiento sobre TWA, profesionales m&#233;dicos e investigadores deben explotar mejor las caracter&#237;sticas t&#233;cnicas de las diversas tecnolog&#237;as disponibles para la evaluaci&#243;n de TWA y estar atento al hecho de que los valores de TWA responden a otros diversos factores, adem&#225;s de medicamentos. Informaciones sobre mecanismos celulares y subcelulares de la TWA est&#225;n fuera del objetivo de este art&#237;culo, pero son referenciados algunos de los principales trabajos sobre este t&#243;pico, con el prop&#243;sito de auxiliar en la comprensi&#243;n de los conceptos y hechos cubiertos en este art&#237;culo. </p>
      <p><bold>Palabras clave: </bold>Arritmias card&#237;acas / prevenci&#243;n y control, muerte s&#250;bita / prevenci&#243;n y control, desfibriladores implantables, Estados Unidos / epidemiolog&#237;a. </p>
      <p>En general, la mayor&#237;a de los casos de muerte s&#250;bita card&#237;aca (MSC) est&#225; relacionada a enfermedad arterial coronaria y cardiomiopat&#237;a no isqu&#233;mica dilatada e hipertr&#243;fica<sup>1</sup>. Igualmente importantes son los casos de MSC registrados en sujetos aparentemente sanos. Entre 1994 a 2003, en el Reino Unido, fueron realizadas autopsias de 453 individuos que sufrieron MSC, todos entre 15 y 81 a&#241;os de edad. En ese conjunto, fueron encontrados 269 (59,3%) corazones macrosc&#243;pica y microsc&#243;picamente normales<sup>2</sup>. </p>
      <p>El reconocimiento preciso de individuos con mayor riesgo inmediato de MSC aun es una cuesti&#243;n en abierto. Muchos factores (adquiridos o cong&#233;nitos; estructurales, funcionales o gen&#233;ticos) est&#225;n relacionados a un aumento en el riesgo de MSC, sin embargo aisladamente no consiguen indicar cuando una persona estar&#225; en el nivel m&#225;ximo de ese tipo de riesgo. La actividad f&#237;sica vigorosa (6 METS o m&#225;s) puede aumentar potencialmente el riesgo de eventos cardiovasculares agudos, sin embargo la rareza de los eventos relacionados al ejercicio da una indicaci&#243;n clara de que es necesario un substrato card&#237;aco espec&#237;fico adicional, seg&#250;n la declaraci&#243;n conjunta de la<italic> American Heart Association</italic> y<italic> American College of Sports Medicine</italic><sup>3</sup>. </p>
      <p>En otras palabras, la n aturaleza aparen tem en te aleatoria de un evento cardiovascular agudo ejemplifica bien que el mecanismo patofisiol&#243;gico t&#237;pico de la MSC no parece ser un gatillo en sincronismo con un substrato arritmog&#233;nico est&#225;tico, para que tenga comienzo una taquicardia ventricular (TV) o fibrilaci&#243;n. Por el contrario, la inestabilidad el&#233;ctrica ser&#237;a din&#225;mica, lo que explicar&#237;a la baja probabilidad de que haya un gatillo espec&#237;fico asociado a un substrato card&#237;aco apropiado<sup>4</sup>. </p>
      <p>&#191;Como medir, entonces, la din&#225;mica de la inestabilidad el&#233;ctrica? Durante las &#250;ltimas d&#233;cadas, fueron realizados diversos estudios en que se probaron formas distintas de medir esa inestabilidad el&#233;ctrica card&#237;aca (o alg&#250;n equivalente v&#225;lido) a partir de una secuencia de latidos de ECG. Tales estudios, de modo general, utilizaron dos abordajes principales: (1) cuantificar como la variable medida estar&#237;a relacionada a la propensi&#243;n a arritmias futuras, y (2) evaluar con que rapidez el miocardio se recompone despu&#233;s de una arritmia el&#233;ctrica peque&#241;a (por ejemplo, extras&#237;stole) y las consecuencias de eso sobre el pron&#243;stico futuro. </p>
      <p>Esos abordajes son semejantes a primera vista, pero tal conclusi&#243;n no es real. Con base en el vocabulario usual de arritmias cl&#237;nicas, en el cual prevenci&#243;n primaria y secundaria significan, respectivamente, prevenci&#243;n antes y despu&#233;s de un evento cardiovascular, podr&#237;amos designar a la primera como una<italic> inestabilidad primaria a arritmias</italic> y la &#250;ltima como una<italic> inestabilidad secundaria a arritmias.</italic> Entre las medidas cl&#237;nicas de inestabilidad primaria, podr&#237;amos enumerar la prolongaci&#243;n del QT, dispersi&#243;n del QT, Potenciales Tard&#237;os y Microalternancia de la Onda T<italic> (T-wave Alternans -TWA). </italic>Turbulencia de la Frecuencia Card&#237;aca, por otro lado, ser&#237;a una medida del grupo de inestabilidad secundaria. </p>
      <p>Esta revisi&#243;n destacar&#225; el papel de la TWA en el panorama actual de la estratificaci&#243;n de riesgo card&#237;aco. Debido a la vasta literatura sobre el t&#243;pico, esta revisi&#243;n se dividir&#225; en cuatro partes. Despu&#233;s de definir TWA y hacer una historia resumida de la misma, ser&#225; retratado en la segunda parte su desempe&#241;o pron&#243;stico en diferentes poblaciones. Una vez que la TWA es un examen que depende esencialmente de la tecnolog&#237;a, la tercera secci&#243;n tejer&#225; consideraciones sobre un aspecto crucial para el desempe&#241;o cl&#237;nico de la TWA: los abordajes tecnol&#243;gicos disponibles y sus consecuentes opciones de an&#225;lisis y limitaciones. La cuarta parte explorar&#225; otros factores que pueden modular los valores e influenciar los ex&#225;menes de TWA. </p>
      <p>
        <bold>Definici&#243;n de TWA y hist&#243;rico resumido </bold>
      </p>
      <p>La llamada TWA es una oscilaci&#243;n de amplitud regular en la porci&#243;n ST-T del trazado de ECG que ocurre con mitad de la frecuencia card&#237;aca. En otras palabras, las alteraciones de amplitud del ST-T se repiten a cada dos latidos, de forma que pueda ser creado un<italic> gold standard</italic> de amplitud con latidos pares y otro con latidos impares. Para fines did&#225;cticos, podemos resumir la historia cronol&#243;gica de la investigaci&#243;n de TWA en tres fases distintas: la transici&#243;n del foco de la investigaci&#243;n, de la TWA macrosc&#243;pica a la TWA microsc&#243;pica; el impacto de la TWA en microvoltios en los protocolos de estratificaci&#243;n de riesgo y en las pol&#237;ticas de salud; y el establecimiento de una base experimental s&#243;lida para los actuales descubrimientos cl&#237;nicos sobre la TWA. </p>
      <p>La TWA macrosc&#243;pica (visual) viene siendo relatada desde los or&#237;genes de la electrocardiolog&#237;a<sup>5</sup>, asociada siempre a un mal pron&#243;stico y considerada un hallazgo raro, hasta la primera publicaci&#243;n del descubrimiento de la TWA invisible (microsc&#243;pica) en la d&#233;cada de 1980<sup>6</sup>. Desde entonces, diversos grupos han estudiado la TWA, cada uno a su manera. Una consecuencia directa de eso fue la revisi&#243;n publicada en 2005, listando m&#225;s de 10 diferentes tecnolog&#237;as para su evaluaci&#243;n<sup>7</sup>, sin embargo sus resultados aun quedaban restringidos a segmentos particulares de la comunidad de investigaci&#243;n cardiol&#243;gica. El paso siguiente - cuando la TWA obtuvo la atenci&#243;n de los cardi&#243;logos cl&#237;nicos, adem&#225;s de los investigadores en cardiolog&#237;a - sucedi&#243; al comienzo del siglo XXI, con la publicaci&#243;n de evidencias de que la TWA conseguir&#237;a reducir el n&#250;mero medio de desfibriladores autom&#225;ticos implantables (CDI) necesarios para conseguir de hecho salvar una vida<sup>8</sup>. </p>
      <p>A aquella altura, la alternancia de la duraci&#243;n del potencial de acci&#243;n intracard&#237;aca (APD-alternans) tambi&#233;n ven&#237;a siendo intensamente estudiada a lo largo de los a&#241;os. En 2002, fueron obtenidas evidencias de que la APD-alternans era el primer eslab&#243;n en una progresi&#243;n ordenada de est&#225;ndares de oscilaci&#243;n de amplitud cada vez m&#225;s complejos, hasta una fibrilaci&#243;n ventricular (FV) durante una isquemia<sup>9</sup>, y tambi&#233;n de que APD-alternans atriales fueron registradas, consistentemente, antes de la transici&#243;n de un flutter atrial para una fibrilaci&#243;n atrial<sup>10</sup>. Adem&#225;s de eso, se descubri&#243; que la alternancia de la TWA y del APD estaban asociadas una a otra en estudios experimentales<sup>11</sup>, pero hasta entonces no hab&#237;a evidencia de que esa relaci&#243;n se mantuviese aun en contextos cl&#237;nicos. </p>
      <p>La tercera fase de la investigaci&#243;n de TWA se inici&#243; con la soluci&#243;n de ese rompecabezas cl&#237;nico. Primero, se demostr&#243; que pacientes con cardiomiopat&#237;a y TV inducible o test positivo de TWA ten&#237;an repolarizaci&#243;n m&#225;s heterog&#233;nea (tanto en el epicardio como en el endocardio) que aquellos sin TV inducible o test negativo de TWA<sup>12</sup>. M&#225;s tarde, la TWA fue relacionada de forma consistente a la APD-alternans endoc&#225;rdica y epic&#225;rdica, de forma que era siempre necesario un n&#250;mero m&#237;nimo de lugares con APD-alternans para que la TWA fuese medida con &#233;xito en la superficie del cuerpo, sin embargo las APD-alternans solas no siempre estaban relacionadas a la TWA en la superficie corporal<sup>13</sup>. </p>
      <p>Actualmente, la TWA se presenta como un equivalente cl&#237;nico v&#225;lido de la APD-alternans, &#233;sta, a su vez, un importante marcador de inestabilidad el&#233;ctrica card&#237;aca. El lector interesado puede dirigirse a diversas publicaciones sobre los mecanismos de la g&#233;nesis de la APD-alternans y su relaci&#243;n con el substrato card&#237;aco arritmog&#233;nico<sup>4,14-17</sup>. Esos fundamentos experimentales agregan valor al desempe&#241;o de la estratificaci&#243;n por la TWA en diferentes poblaciones cl&#237;nicas, revisados en la secci&#243;n siguiente. </p>
      <p>
        <bold>TWA y estratificaci&#243;n de riesgo card&#237;aco </bold>
      </p>
      <p>
        <bold>Enfermedades card&#237;acas coronarias o isqu&#233;micas </bold>
      </p>
      <p>El segundo<italic> Multicenter Automatic Defibrillator Implantation Trial</italic> (Estudio Multic&#233;ntrico sobre Implantaci&#243;n de Desfibrilador Autom&#225;tico Implantable) - MADIT-2 trajo evidencias convincentes sobre una reducci&#243;n de la mortalidad con uso del CDI. Sus hallazgos mostraron una reducci&#243;n global de 31% en el riesgo de mortalidad en pacientes post infartados con fracci&#243;n de eyecci&#243;n ventricular izquierda (FEVI) &lt;30%, no importando si los pacientes estaban en niveles m&#225;s avanzados de la enfermedad, as&#237; definidos a trav&#233;s de la clase funcional NYHA y nivel de nitr&#243;geno urea en la sangre (reducci&#243;n de 28-35%, independiente del riesgo basal de mortalidad en los subgrupos)<sup>18</sup>. </p>
      <p>En 2003, los<italic> American Centers for Medicare and Medicaid Services</italic> (Centros Americanos de Servicios de la Medicare y Medicaid) - CMS decidieron cubrir los costos del tratamiento profil&#225;ctico con CD I para pacientes del tipo MADIT-2 y duraci&#243;n del QRS &gt;120 ms. En 2005, los CMS expandieron la cobertura a todos los pacientes del tipo MADIT-2<sup>19</sup>, pero aun hab&#237;a preocupaci&#243;n con el costo beneficio de esa decisi&#243;n y la necesidad de una mejor estratificaci&#243;n de riesgo<sup>20</sup>. </p>
      <p>La evaluaci&#243;n de la TWA en 177 pacientes del tipo MADIT-2 result&#243; en mejor desempe&#241;o de la estratificaci&#243;n de riesgo que el de la duraci&#243;n del QRS. Pacientes con QRS estrecho (QRS &lt;120 ms) no estaban libres del riesgo de arritmias ventriculares sostenidas (TVS) durante seguimiento de 2 a&#241;os (tasa de mortalidad= 14%, semejante a la del MADIT-2). Por otro lado, el grupo de pacientes con TWA normal registr&#243; apenas 2 muertes en el mismo per&#237;odo (tasa actuarial de mortalidad de 3,8%), mientras que el conjunto con TWA anormal tuvo una HR (hazard ratio) de 4,8 (P= 0,012) para mortalidad por cualquier causa, ajustada para la duraci&#243;n del QRS. En el MADIT-2 fueron necesarios 18 CDIs implantados para salvar una vida, sin embargo, con la estrategia de realizaci&#243;n de ex&#225;menes de TWA, fueron necesarios apenas 7 CDIs para salvar 1 vida<sup>8</sup>. </p>
      <p>Un estudio de cohorte prospectivo englobando 768 pacientes isqu&#233;micos con FEVI &lt;35 % y sin TV sostenida anterior (51% recibieron CDIs), trajo evidencias fuertes de que los beneficios del CDI difieren de acuerdo al nivel de TWA, disminuyendo la mortalidad por cualquier causa (HR = 0,45, 95% CI= [0,27, 076], P= 0,003) de los pacientes con TWA no negativa (positiva o indeterminada), pero sin reducci&#243;n de la mortalidad en el grupo con TWA negativa (HR = 0,85, 95% CI= [0,33, 2,20], P= 0,73). Adem&#225;s de eso, tambi&#233;n fue demostrado que tales hallazgos se debieron en gran parte a la reducci&#243;n de la mortalidad arr&#237;tmica. Con relaci&#243;n a la eficacia de la terapia por CDI, fueron necesarios 9 CDIs para salvar 1 vida en un per&#237;odo de 2 a&#241;os en los pacientes con TWA no negativa, sin embargo fueron necesarios 76 CDIs para salvar 1 vida, en el mismo per&#237;odo, en el grupo con TWA negativa<sup>21</sup>. </p>
      <p>
        <bold>Despu&#233;s de infarto agudo de miocardio </bold>
      </p>
      <p>Con relaci&#243;n a la capacidad de prever eventos arr&#237;tmicos serios, en el contexto de una funci&#243;n card&#237;aca preservada despu&#233;s de infarto agudo de miocardio (IAM), un estudio prospectivo japon&#233;s (n= 1041; 79% hombres) descubri&#243; que la TWA mostr&#243; un desempe&#241;o pron&#243;stico semejante a estudios en poblaciones post IAM con FEVI deprimida. Los tests de TWA fueron realizados al menos 14 d&#237;as post IAM, con 169 (17%) tests positivos, 747 (74%) negativos y 87 (9%) tests indeterminados, sensibilidad general y valor predictivo negativo de 81% y 99,6%, respectivamente, y en an&#225;lisis multivariado HR= 19,7 - 95% CI= (5,5-70,4), P&lt;0,0001 para eventos arr&#237;tmicos<sup>22</sup>. </p>
      <p>El estudio REFINE<italic> (Risk Estimation Following Infarction, Noninvasive Evaluation</italic> - Estimativa de Riesgo Despu&#233;s de Infarto, Evaluaci&#243;n No Invasiva) evalu&#243; el desempe&#241;o pron&#243;stico del examen de tono auton&#243;mico y/o substrato el&#233;ctrico card&#237;aco en la identificaci&#243;n de pacientes con riesgo card&#237;aco m&#225;s alto enseguida despu&#233;s de IAM. </p>
      <p>Resumiendo, ning&#250;n par&#225;metro aislado (TWA, turbulencia de la frecuencia card&#237;aca, sensibilidad barorrefleja), en evaluaci&#243;n realizada 2 a 4 semanas (fase aguda) despu&#233;s de IAM, predijo resultados con &#233;xito. La mejor precisi&#243;n diagn&#243;stica en la fase no aguda (10 a 14 semanas) despu&#233;s de IAM fue obtenida combinando TWA anormal y turbulencia de la FC, m&#225;s FEVI &lt;50%. Ese indicador compuesto identific&#243; correctamente dos tercios de todos los pacientes que sufrieron un ataque card&#237;aco, con sensibilidad de 55%, especificidad de 86% y valor predictivo negativo de 96%. Es importante notar que la TWA medida durante stress por ejercicio o en registros de Holter present&#243; desempe&#241;o semejante, aunque hubiese sido evaluada en cada caso con una tecnolog&#237;a diferente. </p>
      <p>En un an&#225;lisis multivariado ajustado para edad, sexo, IAM anterior y diabetes, el indicador compuesto por Holter y TWA result&#243; en HR= 6,22 - 95% CI = (2,88 - 13,47), P&lt;0,001, y la composici&#243;n con TWA de ejercicio produjo HR = 5,08 95% CI = (2,17 - 11,89), P&lt;0,001<sup>23</sup>. </p>
      <p>A diferencia de los hallazgos del REFINE, otro estudio sobre evaluaci&#243;n de la TWA en el per&#237;odo de 7 a 30 d&#237;as despu&#233;s de IAM (n= 119) result&#243; en 1 7 (14%) tests indeterminados, 50 (42%) tests positivos, y 52 (44%) tests negativos. En un per&#237;odo de seguimiento de 3 a 23 meses, la TWA tuvo el mejor valor pron&#243;stico entre los indicadores (TWA, potenciales tard&#237;os, fracci&#243;n de eyecci&#243;n): 14 de los 15 pacientes con eventos arr&#237;tmicos tuvieron TWA positiva, con la mejor sensibilidad y valor predictivo negativo entre todos los par&#225;metros analizados (93% y 98%, respectivamente; posibilidad relativa<italic> (relative hazard)</italic> de 16,8, P= 0,006)<sup>24</sup>. </p>
      <p>La TWA se mostr&#243; muy eficiente como estratificador de riesgo en los pacientes post infarto del miocardio con FEVI &lt; 30%, independiente el nivel de la enfermedad. De esta forma, como m&#233;todo no invasivo, puede ser una herramienta importante en la evaluaci&#243;n de los pacientes portadores de enfermedad isqu&#233;mica. </p>
      <p>
        <bold>Individuos aparentemente sanos y poblaci&#243;n en general </bold>
      </p>
      <p>
        <bold>Adultos </bold>
      </p>
      <p>La prevalencia de TWA fue evaluada en reposo y durante el ejercicio en sujetos aparentemente sanos (ninguno con medicaci&#243;n permanente), en un total de 48 individuos (edades 21-53 a&#241;os, 29 hombres). Fueron excluidas enfermedades card&#237;acas funcionales y estructurales a trav&#233;s del hist&#243;rico cl&#237;nico y de evaluaci&#243;n por ECG de reposo y ejercicio, y ecocardiograf&#237;a Doppler. Brotes transitorios de TWA fueron observados en 5 (10,4%) individuos. Fue registrada TWA sostenida en 2 (4,2%) sujetos, sin embargo apenas 1 (2,1%) se encuadr&#243; en todos los criterios de positividad, y ninguno de los 48 individuos desarroll&#243; morbilidad por arritmia durante el seguimiento de 12-40 meses<sup>25</sup>. Un estudio m&#225;s amplio (110 sujetos sanos, 20-75 a&#241;os, 76 hombres) fue publicado el mismo a&#241;o, con 5 (5%) sujetos que tuvieron test positivo de TWA, 98 (89%) individuos con TWA negativa, y 7 (6%) con test indeterminado de TWA. Nuevamente, no fue registrada ninguna morbilidad o mortalidad por arritmia durante seguimiento de 32&#177;15 meses<sup>26</sup>. </p>
      <p>
        <bold>Abajo de 18 </bold>
      </p>
      <p>La TWA fue evaluada en 100 voluntarios normales (8-17 a&#241;os, sin historia de enfermedad card&#237;aca, con ex&#225;menes cl&#237;nicos y ECG de reposo normales). El ruido excesivo perjudic&#243; el registro adecuado de datos durante el ejercicio de 16 voluntarios y el reposo de otros 24 voluntarios, sin embargo todos los otros 76 voluntarios tuvieron TWA negativa en reposo. Nueve voluntarios (11% de los tests v&#225;lidos) tuvieron alternancia sostenida, todos con frecuencias card&#237;acas iniciales m&#225;s altas que los criterios adultos usuales: tuvieron variaci&#243;n de 120 a 158 lpm, mientras que el umbral usual de frecuencia card&#237;aca inicial es menor o igual a 110 lpm<sup>27</sup>. </p>
      <p>
        <bold>Poblaci&#243;n en general </bold>
      </p>
      <p>Un subestudio del FINCAVAS<italic> (Finnish Cardiovascular Study)</italic> describi&#243; la evaluaci&#243;n de la TWA en una cohorte de 1.037 pacientes (61,4% hombres, 58 &#177; 13 a&#241;os), extra&#237;da de una poblaci&#243;n general, todos encaminados para test de stress por ejercicio. Las indicaciones cl&#237;nicas para el test de ejercicio inclu&#237;an diagn&#243;stico de enfermedad card&#237;aca coronaria (46%), vulnerabilidad a arritmia inducida por ejercicio (18%), evaluaci&#243;n de capacidad de trabajo card&#237;aco (19%), adecuaci&#243;n del tratamiento para enfermedad card&#237;aca coronaria (24%), levantamiento de perfil de paciente antes de operaci&#243;n invasiva (13%) y evaluaci&#243;n despu&#233;s de infarto de miocardio (10%). La TWA inducida por ejercicio, con punto de corte en 47<italic>&#181;</italic>V o 65 <italic>&#181;</italic>V, fue fuertemente predictora de MSC (RR = 2,9, P = 0,02 y RR = 7,4, P &lt; 0,001, respectivamente), as&#237; como de muerte cardiovascular (RR = 2,6, P = 0,01 y RR = 6,0, P &lt; 0,001), produciendo excelentes valores predictivos negativos, ambos pr&#243;ximos de 98%<sup>28</sup>. </p>
      <p>
        <bold>Atletas </bold>
      </p>
      <p>Jugadores de f&#250;tbol aficionados con y sin prolapso de v&#225;lvula mitral y sujetos sedentarios, pareados por edad (tres grupos de 20 individuos), no tuvieron ning&#250;n test positivo de TWA en protocolos normales de stress por ejercicio<sup>29</sup>. TWA y estudios electrofisiol&#243;gicos (EEF) tambi&#233;n fueron realizados en atletas de competici&#243;n profesionales, de diversos deportes, tanto sanos (n = 48) como con arritmias importantes, sin embargo sin patolog&#237;a arritmog&#233;nica (n = 52). Ning&#250;n atleta sano tuvo test positivo o alg&#250;n evento durante seguimiento medio de 36 meses. </p>
      <p>Por otro lado, 7 en 52 (13,5%) atletas con arritmias tuvieron test positivo de TWA, 5 de los cuales tambi&#233;n tuvieron test positivo de EFF para TV y 1 positivo para taquicardia supraventricular grave (el otro se neg&#243; a hacer EEF). En el grupo de atletas arr&#237;tmicos, los 42 tests negativos de TWA fueron tambi&#233;n controlados por EEF negativa, con excepci&#243;n de uno, espec&#237;ficamente en tratamiento con amiodarona. Entre tanto, este sujeto con TWA negativa/EEF positiva no tuvo ning&#250;n evento durante seguimiento de 25,3 meses<sup>30</sup>. </p>
      <p>Estudio reciente en atletas con arritmias ventriculares (n = 85, 61 hombres) enfatiz&#243; la buena correlaci&#243;n entre resultados de TWA y EEF en esa poblaci&#243;n. N&#250;meros semejantes fueron descriptos para tests positivos de TWA (15 en 85, 18%), con menor frecuencia de tests negativos de TWA (57/85, 68%) y m&#225;s tests indeterminados (13/85, 14%). Todos los atletas con TWA positiva tuvieron resultado de EEF positivo y todos los atletas con TWA negativa tuvieron resultado de EEF negativo. No se encontr&#243; alguna correlaci&#243;n entre resultados indeterminados de TWA y EEF. Con relaci&#243;n a la ocurrencia de eventos, atletas con TWA negativa no tuvieron ning&#250;n evento durante seguimiento medio de 30 meses, sin embargo 5 sujetos con TWA positiva, as&#237; como 2 sujetos con TWA indeterminada, relataron eventos en ese plazo<sup>31</sup>. </p>
      <p>La TWA podr&#225; volverse un buen estratificador de riesgo en individuos normales, sin embargo aun son necesarios estudios m&#225;s profundos, con muestras de tama&#241;os adecuados, para que se pueda contar con datos confiables respecto a estas poblaciones. </p>
      <p>
        <bold>Metodolog&#237;as anal&#237;ticas de TWA </bold>
      </p>
      <p>La TWA es un examen que depende esencialmente de la tecnolog&#237;a usada, una vez que las oscilaciones t&#237;picas de su amplitud (con magnitud del orden de pocos 1/50 mm en aumento normal de 10 mm/mV) est&#225;n m&#225;s all&#225; de la resoluci&#243;n visual del m&#233;dico. Como fue mencionado en la historia, hay diversas metodolog&#237;as de evaluaci&#243;n de la TWA. As&#237;, la elecci&#243;n de la metodolog&#237;a tendr&#225; un impacto directo sobre los valores medidos y las limitaciones cl&#237;nicas de la TWA, aunque los diferentes algoritmos de TWA tengan desempe&#241;o cl&#237;nico semejante<sup>23,32</sup>. Esta secci&#243;n tiene la intenci&#243;n de resumir los conceptos b&#225;sicos, adem&#225;s de distinguir las caracter&#237;sticas y las limitaciones cl&#237;nicas de las m&#225;s relevantes metodolog&#237;as desarrolladas para an&#225;lisis de TWA. De esta forma, fueron considerados relevantes los dos &#250;nicos algoritmos de an&#225;lisis de TWA disponibles comercialmente (m&#233;todo espectral y media modificada m&#243;vil) y las m&#225;s semejantes metodolog&#237;as de investigaci&#243;n (demodulaci&#243;n compleja y media intralatidos). </p>
      <p>
        <bold>&#191;Como es medida la TWA? </bold>
      </p>
      <p>Recordando la definici&#243;n de TWA, el concepto b&#225;sico es la frecuencia. Cuando est&#225; presente, la TWA ocurre siempre en la mitad de la frecuencia card&#237;aca o, en otras palabras, a una frecuencia de 0,5 ciclos por latido (cpl). Siempre que pensamos en detecci&#243;n autom&#225;tica de TWA, esta es la &#250;nica informaci&#243;n disponible<italic> a priori,</italic> ya que nadie sabe de antemano si estar&#225; presente o no, o cual parte del complejo ST-T se alternar&#225;, o aun que magnitud tendr&#225; la alternancia registrada. Es muy parecido al hecho de sintonizar una estaci&#243;n de radio en el auto: sabemos la frecuencia de la radio que nos interesa, pero no podemos predecir si habr&#225; alguna informaci&#243;n relevante en ella, o apenas ruido. </p>
      <p>A partir de esa caracter&#237;stica distintiva de la TWA frecuencia fija - pareci&#243; bastante l&#243;gico (o natural) que las primeras formas de an&#225;lisis de TWA se hayan basado en el rastreo de esa frecuencia de 0,5 cpl. Ese abordaje actualmente es encontrado en el m&#233;todo espectral (SM) y en la demodulaci&#243;n compleja (CD). </p>
      <p>
        <bold>M&#233;todo espectral (SM<italic> - spectral method) </italic></bold>
      </p>
      <p>El SM mide fluctuaciones de la onda T a trav&#233;s de la computaci&#243;n de diferencias punto a punto entre 128 lugares equidistantes en el ST-T en una serie de 1 28 latidos consecutivos alineados (ya descartados los latidos ect&#243;picos y con ruido)<sup>33</sup>. En otras palabras, hay 128 tacogramas semejantes a aquellos usados en el an&#225;lisis de la variabilidad de la frecuencia card&#237;aca. Despu&#233;s, son computados 128 espectros de frecuencia (de ah&#237; el nombre de la metodolog&#237;a - SM), siendo calculada su media. El valor de la TWA es entonces evaluado en la frecuencia de 0,5 cpl (<xref ref-type="fig" rid="es_a20fig01m-body3">Fig.1</xref>). En 1994, fue publicada por la primera vez la adaptaci&#243;n de esa t&#233;cnica a pacientes humanos<sup>34</sup>. Desde entonces, es el m&#233;todo de an&#225;lisis de TWA m&#225;s usado, con la m&#225;s amplia gama de aplicaciones. </p>
      <p content-type="asset">
        <fig id="es_a20fig01m-body3">
          <graphic xlink:href="1678-4170-abc-96-03-0e53-00018-gf01-es.jpg"/></fig>
      </p>
      <p>
        <bold>Demodulaci&#243;n compleja (CD - <italic>complex demodulation) </italic> </bold>
      </p>
      <p>El m&#233;todo CD fue presentado m&#225;s tarde que el SM <sup>36</sup>, como un algoritmo alternativo. B&#225;sicamente este m&#233;todo eval&#250;a solamente la energ&#237;a en la vecindad, pr&#243;xima de la frecuencia de alternancias de 0,5 cpl, al rev&#233;s de calcular las fluctuaciones a lo largo de una amplia franja de frecuencias, como hace el SM. </p>
      <p>A medida que el campo de investigaci&#243;n de TWA madur&#243;, una nueva familia de algoritmos surgi&#243;, todos basados en la comparaci&#243;n de est&#225;ndares de latidos. Ese abordaje actualmente es encontrado en la media modificada m&#243;vil (MMA) y en la media intralatidos. </p>
      <p>
        <bold>Media modificada m&#243;vil (MMA -<italic> modified moving average) </italic></bold>
      </p>
      <p>La MMA crea, recursivamente, dos est&#225;ndares (modelos) de latidos, a partir de cualquier secuencia de latidos v&#225;lidos (siendo un<italic> goldstandard</italic> asociado solamente a los latidos pares, y el otro a los latidos impares). Para explicitar cada uno de los est&#225;ndares de latidos el algoritmo iterativo es el siguiente: las diferencias de amplitud entre el<italic> gold standard</italic> actual (de latidos pares o impares) y el pr&#243;ximo latido v&#225;lido (par o impar) son medidas a lo largo de diversos lugares equidistantes en el ST-T. Cada una de esas diferencias es dividida en X partes iguales (donde X puede ser 8, 16, 32 o 64) y la contribuci&#243;n del latido actual v&#225;lido en la actualizaci&#243;n del latido<italic> gold standard</italic> es entonces limitada a 1/X (llamado de factor de actualizaci&#243;n o fracci&#243;n limitante) de las diferencias entre modelo y latido (<xref ref-type="fig" rid="es_a20fig02m-body3">Fig.2</xref>). Finalmente, los valores de la TWA son mostrados cada 15 segundos, como la diferencia entre los dos est&#225;ndares representativos (y continuamente actualizados) de los latidos pares y latidos impares<sup>37</sup>. </p>
      <p content-type="asset">
        <fig id="es_a20fig02m-body3">
          <graphic xlink:href="1678-4170-abc-96-03-0e53-00018-gf02-es.jpg"/></fig>
      </p>
      <p>
        <bold>Media intralatidos (IBA - <italic>intrabeat average) </italic></bold>
      </p>
      <p>El concepto y las caracter&#237;sticas de la media intralatidos (IBA) son muy semejantes a aquellos presentados en el m&#233;todo MMA. Su marca distintiva es la repartici&#243;n del complejo ST-T en tres intervalos de tiempo (T-inicial a T-pico - que incluye el segmento ST; T-pico a T-final; T-inicial a T-final) y la computaci&#243;n de valores distintos de la TWA para cada uno de ellos<sup>39-41</sup>. </p>
      <p>
        <bold>Factores que Modulan la Twa </bold>
      </p>
      <p>
        <bold>Alteraciones fisiol&#243;gicas y patofisiol&#243;gicas</bold>
      </p>
      <p>Hallazgos iniciales obtenidos en estudios de Holter afirmaron que la magnitud de la TWA responde a fluctuaciones circadianas y alteraciones fisiol&#243;gicas<sup>40,42,43</sup>. An&#225;lisis multivariados de ECCs ambulatorios de 24 horas, registrados en pacientes de la base de datos del ensayo ATRAMI<italic> (Autonomic Tone and Reflejes After Myocardial Infarction -</italic> Tono Auton&#243;mico y Reflejos Despu&#233;s de Infarto de Miocardio), indicaron que niveles de TWA encima del percentil 75 a las 8:00 h de la ma&#241;ana, o en la frecuencia card&#237;aca m&#225;xima (cerca de 47 <italic>&#181;</italic>V) fueron relacionados a posibilidades m&#225;s altas de ataque card&#237;aco (FV documentada) o de muerte arr&#237;tmica durante el per&#237;odo de seguimiento (OR vari&#243; de 4,2 a 7,9, dependiendo de la derivaci&#243;n [electrodo] y del per&#237;odo de tiempo)<sup>38</sup>. M&#225;s tarde, Stein et al.<sup>44</sup> notaron que, en la media, los niveles m&#225;s altos de TWA acompa&#241;aron el ciclo circadiano de aumento de riesgo de muerte s&#250;bita en pacientes con insuficiencia card&#237;aca. Adem&#225;s de eso, se descubri&#243; que niveles de TWA encima de 47 <italic>&#181;</italic>V est&#225;n asociados a riesgo aumentado de MSC. </p>
      <p>Sobre procesos patol&#243;gicos que afectan la magnitud de TWA, Shusterman et al.<sup>40</sup> demostraron un aumento en la magnitud de TWA precediendo el comienzo espont&#225;neo de taqu<italic>&#181;</italic>arritmias ventriculares (TAV). Registros de Holter (n=59) con TAV espont&#225;nea fueron seleccionados del banco de datos del ensayo cl&#237;nico ESVEM<italic> (Electrophysiologic Study</italic> Versus <italic>Electrocardiographic Monitoring -</italic> Estudio Electrofisiol&#243;gico versus Monitoreo Electrocardiogr&#225;fico). Sus resultados muestran que la magnitud de la TWA aument&#243; continuamente de la l&#237;nea basal hasta un pico de 25%, 10 minutos antes del evento. Investigadores del estudio TOVA<italic> (Triggers of Ventricular Arrhythmias</italic> - Gatillos de Arritmias Ventriculares) tambi&#233;n verificaron la existencia de magnitud de TWA significativa antes del comienzo de arritmia, usando electrogramas<sup>45</sup>. Tambi&#233;n fueron registradas alteraciones temporales de TWA post infarto durante los primeros 6 meses despu&#233;s de el evento, probablemente despu&#233;s de remodelado ventricular despu&#233;s de infarto agudo de miocardio<sup>46</sup>. Eventualmente, la TWA en niveles patol&#243;gicos fue fuertemente asociada a la denervaci&#243;n simp&#225;tica card&#237;aca y a la actividad nerviosa simp&#225;tica acelerada en pacientes con cardiomiopat&#237;a idiop&#225;tica dilatada, en evaluaci&#243;n por examen con Iodo-123 23) metayodobenzilguanidina (MIBG) y ecocardiograma<sup>47</sup>. </p>
      <p>Otros estudios investigaron los efectos de stress mental agudo (por recapitulaci&#243;n de recuerdos que indujeron enojo o por aritm&#233;tica mental) sobre la TWA. Kop et al.<sup>43</sup> concluyeron que eso aumenta la amplitud de la TWA en pacientes con CDI, con enfermedad arterial coronaria documentada (n=23), en frecuencias card&#237;acas m&#225;s bajas que las de los protocolos de ejercicio usados actualmente en la evaluaci&#243;n de TWA<sup>43</sup>. Lampert et al.<sup>48</sup> no solamente registraron TWA aumentada debido a stress mental en pacientes con CDI (n=33), sino tambi&#233;n descubri&#243; que las alteraciones de la TWA se correlacionaron bien con alteraciones en la frecuencia card&#237;aca, presi&#243;n arterial sist&#243;lica y catecolaminas<sup>48</sup>, en la misma l&#237;nea de las evidencias anteriores que el stress mental altera tanto el largo de ciclo como la cesaci&#243;n de TV en pacientes con CDI sin isquemia<sup>49</sup>. </p>
      <p>Finalmente, algunas influencias externas tambi&#233;n pueden afectar la TWA. Estimulaci&#243;n de la medula espinal (SCS) es usada actualmente en pacientes con angina no tratable y se supone que tenga un efecto antiarr&#237;tmico sobre el substrato arritmog&#233;nico. El estudio de los est&#225;ndares de TWA para evaluar alteraciones en el substrato arr&#237;tmico indica que pacientes que originalmente tuvieron tests positivos de TWA de alta amplitud cuando el estimulador estaba desconectado, experimentaron un descenso de los valores de TWA (sin embargo, aun con test positivo de TWA) despu&#233;s de 2 horas de la SCS. Despu&#233;s de 24 horas de la SCS, todos los pacientes se volvieron TWA negativos. En esta muestra, todos los pacientes estaban ya en pleno tratamiento con betabloqueantes y ninguna alteraci&#243;n de la frecuencia card&#237;aca basal o de la conducci&#243;n atrioventricular fue observada en tests consecutivos de TWA. Esos hallazgos sugieren un efecto de remodelado dependiente del tiempo sobre el substrato arritmog&#233;nico (evaluado por TWA) independiente de remoci&#243;n simp&#225;tica<sup>50</sup>. </p>
      <p>Otra influencia externa - shocks de CDI durante test de desfibrilaci&#243;n normal (n = 65 pacientes) - aument&#243; agudamente la magnitud de la TWA, mediada en parte por estimulaci&#243;n simp&#225;tica<sup>43</sup>. Adem&#225;s de eso, son necesarios estudios para demostrar si ese aumento de la TWA puede ser asociado al mecanismo m&#225;s com&#250;n de muerte s&#250;bita en pacientes con CDI<sup>51</sup>, i.e., la disociaci&#243;n electromec&#225;nica post shock que sigue a una TV/FV tratada. Sobre este t&#243;pico, un aspecto clave a ser considerado es que problemas en el ciclo celular de calcio - ya asociados a la disfunci&#243;n ventricular mec&#225;nica - son fuertemente relacionados la APD-alternans<sup>4,14,15,17</sup>. </p>
      <p>
        <bold>Consideraciones finales </bold>
      </p>
      <p>El papel pron&#243;stico de la TWA en la estratificaci&#243;n de riesgo cl&#237;nico es cada vez m&#225;s claro, pero aun crea algunas controversias. Por un lado, la literatura actualmente disponible presenta fuertes evidencias de un buen desempe&#241;o pron&#243;stico (notablemente, su valor predictivo negativo) en poblaciones cl&#237;nicas espec&#237;ficas, tales como enfermedad card&#237;aca isqu&#233;mica, despu&#233;s de IAM, cardiomiopat&#237;a no isqu&#233;mica. La TWA tambi&#233;n igualar&#237;a, o tendr&#237;a exactitud pron&#243;stica superior al EEF en otras poblaciones (por ex., atletas con arritmias). Por otro lado, el valor cl&#237;nico de la evaluaci&#243;n de TWA aun es asunto para investigaci&#243;n m&#225;s profunda en muchos de los sus aspectos, particularmente: otras poblaciones cl&#237;nicas de relevancia (p. ej., Chagas) deben ser estudiadas; otros protocolos de estudio (p. ej., comparaciones entre la TWA en Holter y la TWA inducida por esfuerzo o estr&#233;s farmacol&#243;gico) deben ser incluidos; los tecnicismos de cada metodolog&#237;a de medici&#243;n de TWA deben ser considerados correctamente en los protocolos cl&#237;nicos a ser delineados. </p>
      <p>Los pr&#243;ximos pasos en la creaci&#243;n de nuevos protocolos y aplicaciones, en la exploraci&#243;n m&#225;s profunda de las posibilidades cl&#237;nicas de la TWA, o en el llenado de las lagunas actuales en la base de conocimiento de la TWA, siguen una direcci&#243;n: m&#233;dicos e investigadores deben explotar mejor las caracter&#237;sticas tecnol&#243;gicas de las diversas tecnolog&#237;as disponibles para evaluaci&#243;n de la TWA disponibles - cada una con sus propios puntos fuertes y debilidades - conscientes del hecho de que los valores de TWA obtenidos responden la diversos otros factores adem&#225;s de medicaciones. </p>
      <p>
        <bold>Potencial Conflicto de Intereses </bold>
      </p>
      <p>Declaro no haber conflicto de intereses pertinentes. </p>
      <p>
        <bold>Fuentes de Financiamiento </bold>
      </p>
      <p>El presente estudio no tuvo fuentes de financiamiento externas. </p>
      <p>
        <bold>Vinculaci&#243;n Acad&#233;mica </bold>
      </p>
      <p>No hay vinculaci&#243;n de este estudio a programas de postgrado. </p>
      <p>
        <bold>Referencias </bold>
      </p>
    </body>
  </sub-article>
</article>
